

THE NATIONAL INSTITUTE FOR OCCUPATIONAL  
SAFETY AND HEALTH/NATIONAL PERSONAL PROTECTIVE  
TECHNOLOGY LABORATORY (NIOSH/NPPTL) PUBLIC MEETING

Friday, October 13, 2006

NEW AND CONTINUING RESEARCH

Commencing at 8:33 a.m. at the Crowne  
Plaza Pittsburgh South, Pittsburgh, Pennsylvania.

|    |  |     |
|----|--|-----|
| 1  | INDEX  |     |
| 2  | OPENING REMARKS, NPPTL OVERVIEW                  | 3   |
| 3  | ADDRESS BY MS. COYNE                             | 5   |
| 4  | NIOSH PERSONAL PROTECTIVE TECHNOLOGY PROGRAM     | 7   |
| 5  | PPT CROSS-SECTOR HISTORY AND DIRECTION           | 11  |
| 6  | NPPTL PRIORITIES                                 | 23  |
| 7  | GENERAL REMARKS ON THE NPPTL RESEARCH PROGRAM    | 27  |
| 8  | END-OF-SERVICE-LIFE SENSOR PROGRAM               | 43  |
| 9  | NPPTL RESPIRATOR FIT TEST PANELS                 | 75  |
| 10 | NANOTECHNOLOGY AND PERSONAL PROTECTIVE EQUIPMENT | 103 |
| 11 | REUSABILITY OF FILTERING FACEPIECE RESPIRATORS   | 124 |
| 12 | CLOSING REMARKS                                  | 142 |
| 13 |  |     |
| 14 |  |     |
| 15 |  |     |
| 16 |  |     |
| 17 |  |     |
| 18 |  |     |
| 19 |  |     |
| 20 |  |     |
| 21 |  |     |
| 22 |  |     |

## 1                   P R O C E E D I N G S

## 2                   OPENING REMARKS, NPPTL OVERVIEW

3                   MR. BOORD: Good morning, everyone.

4                   Welcome to the second day of our public  
5 meeting to discuss NPPTL activities. I trust that  
6 you all had a pleasant evening in Southwestern  
7 Pennsylvania last evening.

8                   Actually this was the first real taste of  
9 winter that we have had this year. So I don't know  
10 whether you brought that weather to us or exactly  
11 how it got here, but hopefully it didn't diminish  
12 opportunities to experience a little bit of the  
13 area.

14                  For today's meeting, I would just like to  
15 go over a few of the agenda items. The first  
16 presentation that I will deliver this morning, I'll  
17 share it with MaryAnn D'Alessandro. And we will  
18 talk principally about the PPT, personal protective  
19 technology cross-sector programs for the Institute.

20                  We will give you a little bit of the  
21 background on what is being done regarding the PPT  
22 cross-sector.

1           Then for the technical presentations, we  
2 will follow the schedule as identified in the  
3 agenda, and Dr. Ron Shaffer will be leading those  
4 presentations from our research branch.

5           The presentation that's scheduled for  
6 11:10, which is the customer satisfaction summary,  
7 that was the information that we covered at  
8 yesterday's meeting that MaryAnn had addressed to  
9 the audience. So that presentation will not occur  
10 today. So we won't repeat it.

11           And I think with those adjustments, and if  
12 our researcher presentations can stick roughly to  
13 schedule, I think that we should be able to adjourn  
14 our meeting by 11:30 a.m. without very much  
15 difficulty, which I think will be good these for  
16 those of you who need to travel today.

17           Again, I will repeat that our meeting  
18 objective for these two days of presentations is to  
19 provide program information to our stakeholders and  
20 customers.

21           So our interest was not so much to report  
22 results, but basically to inform what we are doing,

1 where we are going, and the types of things that we  
2 are finding.

3           As I mentioned, the discussion this  
4 morning will address some of our personal protective  
5 technology issues. As far as the logistics for the  
6 rest of the meeting, we will follow the same  
7 patterns that we had yesterday.

8           Following the presentations, if there are  
9 questions, we would ask you to go to the middle of  
10 the room, address who you are, who you represent,  
11 and then follow through with the question.

12           The entire process is being recorded and  
13 videotaped, so everybody knows that we do -- will  
14 have a record of the meeting.

15           And before we get into the discussions on  
16 the personal protective technology cross-section, I  
17 would like to ask Judy Coyne to make some  
18 announcements or requests.

19                           ADDRESS BY MS. COYNE

20           MS. COYNE: We are trying to get a new  
21 cable so that we are not lime green over here.

22           I am the communications coordinator and

1 responsible for outreach program. Those are my  
2 mannequins over there, and my hands.

3           When I go to different shows, I like to  
4 have products to take with me, and my mannequins  
5 dressed appropriately. For the firefighter show, I  
6 like to have them dressed, and I like to have  
7 equipment on display that relates to firefighters.

8           If we are in the mainstream -- like we  
9 went to the local general show a couple of weeks  
10 ago -- it was a community event -- I would like to  
11 have various respirators on display and safety  
12 equipment, whether it's -- all kinds of PPT. My  
13 mannequin was dressed with ear protection, safety  
14 goggles, and a respirator. And I like to have them  
15 on display in our building also.

16           So what I need is I need samples of all  
17 kinds of personal protective equipment. And I want  
18 to give everybody a fair representation, and also  
19 high quality, high resolution photos that we can use  
20 in these types of presentations.

21           Some people have been really forthcoming  
22 in providing photos to me. And if you just give me

1 your card, I will be happy to send you an email with  
2 my official request.

3           So I will be here the rest of the day.

4 And to those that have already helped me, thank you  
5 so much. It really makes my job a lot easier.

6           So thank you.

7           NIOSH PERSONAL PROTECTIVE TECHNOLOGY PROGRAM

8           MR. BOORD: Thanks, Judy.

9           The slide that I have on the screen now is  
10 the slide that identifies the various divisions and  
11 offices -- divisions, offices, and laboratories for  
12 the Institute. And as I mentioned yesterday, there  
13 are 16 different offices and laboratories. NPPTL is  
14 one of the laboratories comprising the institute.

15           The research program and the research  
16 activities for the institute are being geared around  
17 the industry sector program portfolio that I  
18 discussed yesterday.

19           The industry sectors are as identified in  
20 the right-hand column, the agriculture,  
21 construction, through wholesale and retail trade.  
22 The cross-sector programs are identified in the

1 center column of the slide. And the personal  
2 protective technology cross-sector program is being  
3 managed by the laboratory, by NPPTL.

4           As discussed yesterday, and mentioned by  
5 Frank Hearl, the institute is working with the  
6 National Academies of Science to review the various  
7 programs and research activities for the laboratory.  
8 In that regard, we have already started to follow  
9 through that review process.

10           Two of the program areas have already been  
11 through the National Academy review. And those are  
12 the mining program and the hearing loss cross-sector  
13 program.

14           The mining program has, as I say, has  
15 completed the review. And the National Academy  
16 report on that review will be available on the NIOSH  
17 website in November for those of you who are  
18 interested in seeing that.

19           The hearing loss review has also been  
20 completed, and that program, I believe, is available  
21 on the NIOSH website currently.

22           So those two are available.



1           The respiratory disease studies National  
2 Academy review is scheduled to begin with the first  
3 meeting with the National Academies on October 26  
4 and 27. And that is an open public meeting, so if  
5 you have an interest to engage and participate in  
6 that activity, the dates are October 26 and 27.

7           Other sector programs that will go in  
8 front of the National Academies over the next six  
9 months include the construction program and the  
10 personal protective technologies program.

11           We are scheduled to have our Academy  
12 review beginning in June of next year. So that  
13 gives you a little idea of the future direction for  
14 the NIOSH activities and the research program  
15 portfolio.

16           Regarding the personal protective  
17 cross-sector program, as I mentioned, the laboratory  
18 is responsible for developing that program.

19           It should be noted that the activities  
20 relative to personal protective technologies for the  
21 institute are not uniquely concentrated at NPPTL.  
22 We are responsible for identifying the program and

1 leading the program, but there are other divisions  
2 and laboratories that are engaged in various PPT  
3 activities.

4           The cross-sector team that we have  
5 assembled to prepare our package -- and our National  
6 Academy package really has two components to it.

7           The first component is a strategic  
8 planning and strategic direction for the future  
9 activities for personal protective technologies.  
10 And the second component is an evidence package  
11 looking backwards in time to identify what has been  
12 done and the outputs and the impacts of the previous  
13 work.

14           So our personal protective technology  
15 cross-sector team is engaged in both of those  
16 activities.

17           That team is being managed -- I am the  
18 program manager for that team. And our program  
19 coordinators are Maryann D'Alessandro from the  
20 laboratory, and Jeff Welsh from PRL, who many of you  
21 may know. And the program assistant coordinator is  
22 Angie Shepherd, who you heard from yesterday.

1           The team, the composition of the team is  
2 comprised of members from around the institute. So  
3 you can see the team membership identified on the  
4 slide. And you will note notice that there are  
5 representatives from DSR, DRDS, DSHEFS, DART, and  
6 PRL actively engaged in the process.

7           Plus, there will be other participants in  
8 preparing the evidence package and preparing the  
9 strategic planning that will come in and provide  
10 input to the team, but then not be there as a  
11 continuing team member.

12           So this is the team that we have assembled  
13 for the program.

14           And at this point, what I would like to do  
15 is turn it over to Maryann, who is a program  
16 coordinator, who will walk through some of the  
17 activities that we have already completed, where  
18 that program stands, and give you some idea of what  
19 the direction forward for PPT cross-sector is.

20           PPT CROSS-SECTOR HISTORY AND DIRECTION

21           MS. D'ALESSANDRO: Good morning. I just  
22 want to walk through what we have been doing over

1 the past year so you see how active the PPT  
2 cross-sector is within NIOSH and how NPPTL fits into  
3 that overall structure.

4           First quarter 2006, which is October  
5 through December last year, the PPT cross-sector met  
6 weekly. That was Les and I and Jeff Welsh. And we  
7 developed a draft mission, vision, definition, and  
8 logic model or value creation system, as you saw Les  
9 present yesterday and the day before, and discussed  
10 the strategy for the PPT cross-sector.

11           And then, beginning in January 2006, we  
12 began monthly meetings with the entire team. And  
13 over that time, we refined that mission, vision, and  
14 definition in the logic model with the entire team,  
15 which, again, encompassed all divisions within NIOSH  
16 and a big sector of NPPTL.

17           After that was refined -- actually, here's  
18 the mission, vision, and definition then that now --  
19 this is for the overall NIOSH -- for the institute,  
20 NIOSH mission, vision, and PPT definition. And then  
21 NPPTL is a smaller, more focused part of that.

22           So the mission is to prevent work-related

1 injury and illness by advancing the state of  
2 knowledge and application of personal protective  
3 technologies. And the vision is be the leading  
4 provider of quality, relevant, and timely PPT  
5 research training and evaluation.

6           And we spent a lot of time going over what  
7 the mission and vision should be, and we thought  
8 that this was a pretty good representation of  
9 overall what the PPT mission and vision statement  
10 should be for the cross-sector.

11           But we are interested in your feedback,  
12 and we will be opening a docket on this as well.  
13 And that hasn't been opened yet, but we look forward  
14 to your input there.

15           And then with the definition, the  
16 technical methods, processes, techniques, tools, and  
17 materials that support the development and use of  
18 PPE worn by individuals to reduce the effects of  
19 their exposure to a hazard.

20           We wanted to make sure that the PPT did  
21 not include things like flashlights, for example,  
22 things that would be handheld, or environmental

1 sensors, that the PPT definition encompassed those  
2 things that would protect you from various hazards.  
3 And that's how we resulted in the definition that we  
4 have there.

5           Again, we do look for feedback. This is  
6 draft at this time, and our package is not due to go  
7 to the National Academies until next spring.

8           I don't know if you can see this, probably  
9 not. But we will be posting this logic model -- can  
10 you see that at all or is -- not at all. Okay. We  
11 will post this ...

12           But if you remember the value creation  
13 system that NPPTL has, talks about inputs to our  
14 activities, the activities that are being conducted  
15 throughout NPPTL.

16           I'll put that we expect the intermediate  
17 outcomes and end outcomes. And this is what this  
18 encompasses. But this is for all of NIOSH, so it's  
19 a lot more detailed.

20           And when we put this together, we also  
21 included certification. We pulled that out of the  
22 overall logic model. So that is included

1 separately, but it is also within there. But it's  
2 easy to identify that because we thought that was a  
3 very important part of what PPT is doing in the  
4 institute, so we pulled that out. But it was really  
5 difficult to develop this because of the unique rule  
6 that certification plays in the NIOSH.

7           Most of the programs that are undergoing  
8 review have just a research component. Therefore  
9 several have other components to them, like the  
10 health hazards evaluation program.

11           But really NPPTL, the certification  
12 program is unique to NIOSH. And that is something  
13 that we really have to figure out how we are going  
14 to describe this, describe our past, and then how we  
15 move forward into the future for the National  
16 Academies when the review happens.

17           But we will post this along with all of  
18 the slides that I have here today. But if I could  
19 just -- is that easier to see?

20           That covers the same things that are in  
21 the logic model, and I'll just briefly go over what  
22 we have considered in putting together our past and

1 moving forward to the future.

2           The inputs that we have been looking at  
3 are, first of all, what the industry sector goals  
4 and draft goals are.

5           As Les talked about, all of the eight  
6 sectors in NIOSH, the industry sectors which include  
7 mining, construction, health care -- I'm at a loss,  
8 but all of those eight industry sectors. They are  
9 all developing goals and draft goals at this time.  
10 And we have considered those inputs into what PPT  
11 goals should be.

12           We have also looked at all of the  
13 surveillance data that is out there, all of the  
14 surveillance data that NIOSH has collected and  
15 surveillance data that is being collected in other  
16 places.

17           We, of course, have considered stakeholder  
18 needs, something NPPTL has always done, but NIOSH  
19 has not necessarily done that very well in the past.  
20 So we are including that.

21           Also, townhall meeting feedback. The NORA  
22 program and NIOSH had many townhall meetings last



1 year. We went through all of the feedback from  
2 those meetings. Everything that had a PPT component  
3 to it, we looked at and saw where that fit into  
4 where PPT should go in the future.

5           And also, of course, the national  
6 priorities. The mining issues are high priority  
7 right now. Pandemic influenza considerations are  
8 also high priorities. And also the feedback from  
9 our committee on PPE has well has been an input to  
10 developing the goals that we have at this point.

11           So now, we have developed draft goals, and  
12 now we are trying to identify where is the best fit  
13 for the various goals.

14           Should -- the goals that we have, once we  
15 identify activities that should be conducted and be  
16 associated with those goals, where they should they  
17 fit. Should they be activities be conducted  
18 intramurally? Should we put them extramurally into  
19 the grant process? Should we recommend they go  
20 other places other than NIOSH? Or should we do them  
21 in-house, like a lot of our activities went through  
22 a contract mechanism?

1           So we are doing all of that up front  
2 before we look at our current activities that we are  
3 doing just so we don't try to focus on what we are  
4 doing right now and say that this is where we should  
5 go in the future.

6           So we are looking at all of the needs from  
7 those inputs.

8           Now we are seeing where do all of the  
9 things that we should be doing fit into what we are  
10 currently doing. Then we will identify and  
11 prioritize the gaps, and then develop measures and  
12 metrics.

13           That's where we are right now, trying to  
14 put measures and metrics to the goals that we have  
15 developed and expand upon those goals for various  
16 industry sectors.

17           The current activities are on the  
18 right-hand side, and we are currently developing  
19 content for the website. Each sector and  
20 cross-sector that is being evaluated by the National  
21 Academies has to describe the past with a website  
22 and evidence package. We are putting that together

1 right now.

2           Rand is being used as a consultant.

3 Primarily, so far, they have helped us with the  
4 logic model, in refining that. And then we are also  
5 looking at what current external PPT activities are  
6 going on that we may be able to exploit.

7           We have developed quad charts for all of  
8 our projects, which include the objective of all of  
9 our programs, who the stakeholders and partners are,  
10 milestones that are achieved, and what we anticipate  
11 the outputs and outcomes to be.

12           And we have to develop for each of those  
13 projects compendiums, so just descriptions of all of  
14 those projects and where we intend for those to go.

15           For the first quarter of 2006, we are  
16 refining the mission, vision; definition, and logic  
17 model that I showed. We are continuing the monthly  
18 meetings that we have had.

19           And in addition to the monthly meetings  
20 with the whole team, we have broken the team into  
21 separate groups. We have a health and a safety  
22 group.

1           And then within those two groups, we have  
2 groups that focus on respiratory protection or  
3 inhalation hazards, dermal hazards, or protective  
4 clothing and ensembles, hearing protection, hearing  
5 loss hazards, head protection, and eye and face  
6 protection.

7           In the second quarter, we -- that's what  
8 we have done already. Gone over that. Now, here we  
9 are with the goals. Somehow they got backwards.

10           The first goal that we came up with,  
11 Identify and develop performance requirements and  
12 evaluation criteria for PPT to achieve harmonized  
13 standards to improve the quality and performance of  
14 PPE through all lifecycle stages.

15           That's a mouthful. It encompasses a lot,  
16 and it will be broken down into a lot of  
17 subcategories. And that's currently what the teams  
18 are doing at this time is breaking that 1.1, 2, and  
19 3 down further and focusing on each industry sector  
20 and aligning what all of the sectors are doing in  
21 their goals with the PPT goals that we have.

22           The second goal is to develop

1 informational materials to provide guidance to  
2 identify appropriate PPE for all lifecycle stages.

3           The second stage, after we have the first,  
4 go ahead, develop the standards that are needed in  
5 the performance requirements. Then guidance is  
6 needed to address those issues that were developed  
7 in goal one.

8           And that is part of the second goal,  
9 guidance in all of those areas, and where we should  
10 be focusing, and in those five areas that address  
11 the hazards that I mentioned.

12           Then in Goal 3, conduct research to  
13 address personal protective technology knowledge  
14 gaps and improve existing technologies. Then the  
15 end of the -- beginning and the end of the cycle is  
16 to identify what the research is that should be  
17 conducted to address the standards needs that have  
18 been identified that then could be put into the  
19 standard and then into the guidance ultimately.

20           So now, for the remaining fourth quarter  
21 '06 and now this first quarter of 2007, we are  
22 continuing this evidence package development to

1 describe the past and the history of the program.

2 And then we are also incorporating partner and

3 stakeholder lists and letters.

4           What we need to do is, -- what the National

5 Academies did with the mining and the hearing loss

6 programs is they went to the stakeholders and the

7 partners that they had identified in all of their

8 projects and they actually contacted them and asked

9 them to come in.

10           So what we were going to do is solicit

11 people up front who think that they should be

12 involved or could have a role in what we are doing

13 and get them involved up front in the process

14 instead of at the end.

15           And that's what we are doing now is

16 identifying who those partners and stakeholders are

17 in PPT and perhaps seeing what has been developed in

18 the past, perhaps letters that came in on success

19 stories or areas where we needed to improve and how

20 we responded to that and get those stakeholders

21 involved.

22           So when the docket is opened, I would

1 encourage you to, if you are one of those partners  
2 or stakeholders, to indicate that you would be  
3 interested in participating in this process.

4           In the second quarter '07, we will  
5 continue to refine and finalize the evidence  
6 package, and we do intend to get that out for others  
7 to review and provide input prior to submitting to  
8 the National Academies in around the May time frame.

9           So, again, we do want your feedback. And  
10 if you have any questions, Les or I could answer  
11 those or anyone on the team. Most of the team  
12 members, or a lot of them, are in the room. And  
13 thank you for your attention.

14           Are there any questions?

15                           NPPTL PRIORITIES

16           MR. BOORD: Thanks, Maryann.

17           I think yesterday in the presentation, I  
18 went over some of the priorities for the laboratory.

19           And I just want to run down those  
20 priorities because I think it's kind of important  
21 that you can see through the course of what we  
22 presented yesterday and the discussions and some of

1 the comments that have been made, the discussions  
2 that we have today and the presentation that we just  
3 had relative to PPT, I think you can start to see  
4 perhaps some thread winding through everything that  
5 we are doing, and our focus for the laboratory, our  
6 standards focus.

7           I think in the presentations yesterday,  
8 you certainly heard and see the connections that we  
9 make between our research and development programs  
10 and national, international, and federal standards.

11           Partnerships. Partnerships are key to be  
12 being able to accomplish anything. So partnerships  
13 continue to be a driving priority for the laboratory  
14 to make things happen.

15           Personal protective technology  
16 evaluations. And our focus is to improve the  
17 technology of evaluation for our respirator  
18 certification program. Okay.

19           Some of the things that Heinz discussed  
20 relative to -- and Bill Newcomb relative to our  
21 quality assurance program module and our TIL  
22 programs that we talked about, these are



1 improvements to the way we certify our equipment.

2           Science Center of Excellence. The  
3 keywords there are robust evaluations.

4           We know that the institute is going down  
5 the road to work with the National Academy as the  
6 premier review activity. And that activity and  
7 association with the National Academy is impacting  
8 NPPTL and the programs and projects that we have  
9 going on with the National Academy in parallel to  
10 the institute activities.

11           And the PPT cross-sector is moving forward  
12 for a major review by the National Academy next  
13 year.

14           Outreach. Again, outreach is very  
15 important to us. We have talked many times, and you  
16 have heard many times in the presentations yesterday  
17 about the outreach activities and our interest to  
18 facilitate and create dialogue with our stakeholders  
19 and partners. It is important to keep the ship  
20 moving forward and forward in the right direction.

21           Human resource excellence, it is  
22 imperative that as we look inside and inward towards

1 our operation in the institute, that we have a good  
2 human resource focus so that we are accomplishing  
3 things with qualified people and expertise.

4           So I think that you can see that there is  
5 a thread that's weaving through all of the  
6 activities of the laboratory and certainly are  
7 achieving performance excellence.

8           Our APEX program is really, for the  
9 laboratory, it's kind of the web that pulls  
10 everything together because it's what gives us the  
11 direction and the drive to do the outreach, to  
12 sponsor and support the evaluations.

13           So the APEX program is really the  
14 mechanism that we use to keep things going and to  
15 accomplish our objectives.

16           So with that, what I would like to do  
17 is -- we are -- I'm going to go backwards. We are  
18 going to have a slight agenda change. And I will  
19 introduce Dr. Ron Shaffer who will give an overview  
20 of some of the research activities.

21           Following Ron's presentation, we will take  
22 a short break. And that break will be used to try

1 to get our projector set up so that they can operate  
2 on both screens.

3           So with that, I would like to introduce  
4 Ron.

5       GENERAL REMARKS ON THE NPPTL RESEARCH PROGRAM

6           MR. SHAFFER: Thanks, Les.

7           For those of you who are on this side of  
8 the room and are going to have trouble seeing the  
9 slides, I only have eight of them in this  
10 presentation. This is a longer version of what I  
11 did yesterday when I introduced the poster session,  
12 so there's not a lot of -- there's no data, no  
13 pretty graphics in particular.

14           But if you did want to see, I suggest you  
15 move over to this side of the room or towards the  
16 back because you can see the slides a little bit.  
17 But these will be posted to the web for download at  
18 a later time, so you can certainly see them later.

19           I wanted to give basically an overview of  
20 the research branch.

21           Following my discussion, and after the  
22 break, we will have four technical talks about

1 specific projects.

2           But I just want to give you, again, the  
3 high level overview of all of the types of things  
4 that we are working on so you can see the diversity  
5 of projects and maybe see something that piques your  
6 interest where we can work together on the project.

7           For those of you that were here yesterday,  
8 in my introductory remarks and also for Maryann's  
9 discussion at the end of the day yesterday, you  
10 learned a little bit about a survey that we  
11 conducted with the Office of Personnel Management, a  
12 stakeholder survey, manufacturer survey.

13           Well, one of the questions in that survey  
14 was respondents were asked about their awareness of  
15 the NPPTL research portfolio.

16           And the part of the responses that we got  
17 back were -- I think manufacturers were about 30 --  
18 gave us a favorable rating about 38 percent of the  
19 time, users about 56 percent of the time.

20           So obviously there is an opportunity there  
21 to improve our outreach efforts. And so part of the  
22 discussions this morning -- my speaking here is to

1 really try to improve that a little bit.

2           So today, I'm just going to talk about the  
3 projects within the research branch, not about the  
4 research projects that were discussed in the  
5 afternoon yesterday that are undertaken by policy  
6 and standards development.

7           The focus areas for the laboratory, as I  
8 discussed yesterday, are these four, respiratory  
9 protection, certainly the bread and butter for the  
10 laboratory. Sensors and electronics, primarily  
11 where it's integrated with personal protective  
12 equipment.

13           Protective clothing ensembles, and then  
14 human performance. Human performance being trying  
15 to understand how PPE affects the user, what kind of  
16 burden it places upon the user.

17           We have a portfolio of research projects,  
18 and it will range somewhere between 10 to 15  
19 projects at any given time. They are all at various  
20 stages of development.

21           And so you will see today, we have got  
22 projects that are at the very early formative stages

1 where we don't even have a protocol written. We are  
2 still working on that, trying to get our  
3 partnerships developed.

4           Some very mature projects that are at the  
5 end of their life stage and have been very  
6 successful.

7           So, for example, some of the work that  
8 Ziqing will talk about later, that's a project  
9 that's been around since about 2001-2002 time frame.  
10 And it's had a number of publications.

11           Pengfei Gao has a poster on a  
12 decontamination of chemical protective clothing,  
13 again, another project that's been around since  
14 about 2001-2002 time frame. And we have seen a  
15 number papers come up, a very productive research  
16 project.

17           So we do have a diverse mix of new ones as  
18 well as the projects that are at the end of their  
19 lifecycle.

20           And all of the projects that we will talk  
21 about today have a standards focus to them. They  
22 impact a standard or some policy or recommendation

1 that CDC or NIOSH puts out. The standard could be  
2 an ASTM standard, an NFPA standard, or as well as in  
3 something in 42 CFR. So we have projects that span  
4 that entire gamut.

5           The staff at the lab, we have about 20  
6 researchers, including contract staff that support  
7 the group, the postdoctoral fellows. I think 13 of  
8 us are federal employees, the diverse backgrounds.  
9 Six Ph.D.s, degrees from the industrial hygiene to  
10 chemical engineering to chemistry. So a very broad  
11 background.

12           The budget of the research branch is on  
13 order of 2 to 4 million dollars a year, depending  
14 upon the priorities of the lab and the needs of the  
15 research projects.

16           The work that we do is a mix of in-house  
17 work and work that we fund at universities. In the  
18 earlier days of the lab, it probably was more  
19 heavily weighted towards work that was funded at  
20 universities or other government agencies, and that  
21 was while we were building up our in-house  
22 capabilities.

1           We have had a number of renovations done  
2 to our labs, so we have expanded our capabilities.  
3 So now we are probably a little more weighted  
4 towards in-house research. But we still try to keep  
5 a balance of extramural and intramural research.

6           And what I'm going to do is, the next  
7 slides, I'm going to have one slide or two on each  
8 one of these four focus areas.

9           In the area of respiratory protection,  
10 this is basically -- slide categorizes how we break  
11 up the research.

12           Basically, you know, the hazard or the  
13 inhalation, the total inward leakage to a respirator  
14 user primarily comes from two means, either  
15 particles or gases would penetrate through the  
16 filter or the cartridge, or they cause a leak around  
17 the face seal.

18           So we obviously have projects that are  
19 interested in both of those areas.

20           In the aerosol filtration studies work,  
21 I'll be talking a little bit later about work that  
22 we are doing in nanoparticles, and there's a poster



1 obviously about that.

2           Sammy Rengasamy talked about some  
3 bioaerosol work that we did, and that also is a  
4 poster over on this side of the room.

5           Ziqing Zhuang will talk later about the  
6 respirator fit test research that we have been  
7 doing, primarily in the area of facial  
8 anthropometrics, measurements of human face, and  
9 number of applications of that technology that he  
10 will be discussing later.

11           And then in the area of influenza  
12 pandemic. So this is what we would consider more of  
13 an emerging issue. And we have got one project  
14 listed here under that category, and that's a  
15 project that is titled reusability of filtering  
16 facepiece respirators.

17           Although it does cover more than just the  
18 reusability, it also considers re-aerosolization and  
19 risk assessment, you know, handling a respirator  
20 that's been used, been potentially exposed to an  
21 infectious aerosol.

22           That's a new start for this fiscal year.

1 Jon Szalajda will have a presentation about that  
2 later.

3           In the area of the sensors and  
4 electronics, our focus at the lab has primarily been  
5 on end-of-service-life indicators, either new sensor  
6 technology or mathematical models. And Jay Snyder  
7 will have a presentation after the break that will  
8 go through this in a lot more detail.

9           Protective clothing ensembles research is  
10 a major focus area. If you look at the breakout of  
11 our projects by funding or by budget, about  
12 50 percent of the work goes in respirators or sensor  
13 projects that are all focused on respirators, and  
14 the other half of the funding goes towards  
15 protective clothing and human performance, which are  
16 closely aligned in our projects today.

17           So this just -- this slide just lists the  
18 various projects that we are currently working on.  
19 And there are posters on the first two, Pengfei Gao  
20 has a poster over here on the decontamination of  
21 chemical protective clothing. And Angie Shepherd  
22 has got the poster and the display over there on the

1 emergency medical protective clothing.

2           The EMS project supports NFPA 1999 work.  
3 And Pengfei's work on the chemical protective  
4 clothing has resulted in at least one work item at  
5 ASTM on some software that he has developed for  
6 automating permeation calculations for chemical  
7 permeation testing.

8           The third bullet on here is development of  
9 bench and MIST protocols for particulate penetration  
10 measurements through protective clothing and  
11 ensembles. That's a new start for us -- actually,  
12 it was an FY '06 new start.

13           The first year was primarily spent  
14 researching the area and getting some preliminary  
15 data in order to write a proposal. That proposal  
16 has been sent out for peer review.

17           We got the responses back a couple of  
18 weeks ago, and Pengfei and his team are currently  
19 going through the process of revising the project  
20 plan based on the peer reviewer's comments.

21           The last project -- and, actually, I  
22 should say that part of the nanotechnology talk I

1 will give later is actually -- is an aspect of  
2 this -- the third bulleted project as well.

3           The final project listed as a new start  
4 for FY '07, so it is at very early formative stages  
5 of just conceptual planning of how we want to  
6 execute that project, and that's going to be led by  
7 Angie Shepherd.

8           And the focus of that project is to look  
9 at various preconditioning methods that are used in  
10 NFPA standards, such as the 1971 structural  
11 firefighting and 1994 protective ensembles for  
12 terrorism response.

13           And she will be looking at things like  
14 laundering, abrading, heating, and flexing and  
15 attempting to correlate that with wear trials.

16           And that's an area where NFPA has  
17 indicated a need for some good scientific data in  
18 order to support the performance requirements and  
19 test methods.

20           In the area of human performance, we have  
21 the poster over in the back corner there on Project  
22 HEROES. This is certainly something we have spent a

1 lot of time working on. This is a project that is  
2 funded by the Technical Support Working Group,  
3 otherwise as TSWG. It's actually managed by the  
4 International Association of Firefighters, the IAFF.

5           And our piece of the project is to focus  
6 on the physiological testing of that prototype  
7 HEROES ensemble.

8           And we have also been heavily involved in  
9 developing the standards, revising the NFPA  
10 standards that would support this type of a new  
11 technology. John Williams is the project officer of  
12 the first two efforts on this slide.

13           The second one physiological models and  
14 countermeasures is more of a broader project that's  
15 looking at new test methods for assessing the burden  
16 of PPE, looking at cooling garments and also  
17 physiological monitoring equipment.

18           And the -- both projects have gone -- at  
19 least the protocols for how we are doing the testing  
20 have both gone through external peer review and  
21 either are currently in data collection mode or  
22 subject -- trying to get the subjects signed up for

1 the testing.

2           The final bullet is a new start for FY'07,  
3 so that's why you don't have a poster on some of the  
4 new -- the very new projects. We just don't have  
5 enough material even to put a -- to really create a  
6 good poster on.

7           That is project entitled metabolic  
8 evaluation of N95 respirators with protective  
9 covering. So this bullet actually could go under  
10 the respiratory protection slide, but it really does  
11 focus more on the human performance.

12           The idea behind that project -- let me  
13 explain this in a little more detail because it  
14 might be of interest to this audience.

15           The National Academy of Science's  
16 Institute of Medicine produced that report that was  
17 discussed a number of times yesterday on the  
18 reusability of face masks.

19           One of the recommendations that came out  
20 of that report was that it -- to extend the lifetime  
21 of an N95 respirator, you might want to use a  
22 surgical mask to cover the respirator. The idea is

1 that if droplets came into contact with that, the  
2 surgical mask, you could take that and off and  
3 potentially reuse your respirator. Again, this  
4 would primarily be only used in an emergency  
5 situation, like a pandemic where you had a shortage  
6 of respirators.

7           What got us thinking a little bit about  
8 that was how would that affect the metabolic gas  
9 responses inside the mask.

10           We certainly know that there are a number  
11 of papers that have come out that show that higher  
12 levels of CO2 in healthcare workers wearing  
13 respirators can give headaches and generally make  
14 it, you know, something you would not want to wear  
15 for six, seven, eight hours at a time. And so how  
16 would having an extra piece of material in front of  
17 the respirator affect that?

18           And so we are doing a very simple set of  
19 experiments with the automated breathing and  
20 metabolic simulator to look at the CO2 and oxygen  
21 levels inside a N95 respirator while the surgical  
22 mask is worn and then while there was no surgical

1 mask, and doing some comparisons.

2           So that project, the proposal has -- is  
3 certainly in internal review right now. It has been  
4 written.

5           So that's the projects that we have. I  
6 just want to emphasize a few key points here.

7           We have a standards focus at the  
8 laboratory. I think that's evident in reviewing the  
9 posters and talking to the researchers. Our  
10 projects support various ASTM, NFPA, ISO standards  
11 as well as 42 CFR, and guidance and policy  
12 recommendations that CDC or NIOSH puts out the door.

13           So we have a very clear linkage in what we  
14 call r2p, or research to practice, where we have got  
15 an end outcome in mind for the projects at the very  
16 beginning.

17           You will see that we have a diverse mix of  
18 projects from across all four focus areas.

19           Most people, you know, when they know --  
20 hear of NPPTL or NIOSH think respirators, and that's  
21 what we -- that's all we do. But, actually, we do  
22 have a broad mix and have been very diligent in



1 making sure that we have a really good 50/50 type  
2 split of protective clothing and respirator  
3 research.

4           And finally, I just want to make a few  
5 remarks about research to practice.

6           Through partnerships, obviously this is  
7 where you can get involved. Certainly, whether  
8 you're a user or a manufacturer, there is  
9 opportunities to help us improve the research, which  
10 will ultimately benefit you as well.

11           Input can happen through, you know,  
12 appearing before the National Academy of Sciences to  
13 make a presentation or participating on a committee,  
14 through the various focus groups that Maryann and  
15 her team put together.

16           You can be involved in peer reviewing our  
17 proposals or peer reviewing the projects at the end  
18 of the -- or not the projects, but the outputs, the  
19 reports, the manuscripts at the end of the project.

20           So there is opportunities to participate  
21 from beginning through the end.

22           And certainly if you have ideas for

1 research that you think we would should be doing, we  
2 don't have a docket number open for that, but  
3 certainly an email to me or anybody on the  
4 management team, we will be happy to consider those  
5 within our process for selecting our research  
6 projects because certainly we don't have the, you  
7 know, the monopoly on all the great research ideas  
8 that are out there.

9           So we certainly welcome your input into  
10 the projects and how we select which ones we work on  
11 and which ones we don't.

12           So with that, I will close and take any  
13 questions. And then we will, like Les said, we will  
14 have a short break while we try to fix the  
15 projector.

16           And Jay's presentation has a lot of great  
17 graphics in it, so we definitely need to -- and lots  
18 of data. So we need to make sure the projector is  
19 fixed, or we move to this side of the room.

20           So any questions? All right. Thanks.

21           MR. BOORD: Thanks, Ron. So we will take  
22 a few minutes break to fix the equipment, and we

1 will give you an announcement before we begin.

2 Thanks.

3 (A recess was taken.)

4 MR. SHAFFER: We are going to -- because  
5 we had the break a little bit earlier, we are going  
6 to go ahead and do all four technical presentations  
7 back to back with Q and A in between them. And then  
8 we will wrap it up with a few remarks by Les Boord,  
9 our director.

10 So with that, I will turn it over to Jay  
11 Snyder, who is going to talk about our  
12 end-of-service-life sensor program.

13 END-OF-SERVICE-LIFE SENSOR PROGRAM

14 MR. SNYDER: Good morning, again. Seems  
15 like we have done this before, same time, same  
16 place, only a day difference.

17 And I thought the problem had been solved  
18 of being ambidextrous with two laser pointers  
19 simultaneously with having only one projector, but I  
20 see we have got two back, so bear with me.

21 This morning, for the next 20 minutes or  
22 so, I wanted to talk to you about our

1 end-of-service-life program and give you some  
2 details regarding it.

3           And in doing so, I will be covering a  
4 cartridge simulator, which we have constructed and I  
5 have brought with me today. So if you would like to  
6 see that, please stop by later. I would be happy to  
7 show that to you.

8           It also has a sensor arrangement in it, et  
9 cetera.

10           And I also wanted to give you some real  
11 details about our CMU sensor development program,  
12 which we have been working with them for the past  
13 several years.

14           Yesterday, I mentioned to you about some  
15 of our stakeholders' interests in end of service  
16 life, but the one I didn't mention that is really  
17 quite important is the regulatory requirement that  
18 OSHA has in their 1910 standard, which says that an  
19 end-of-service-life indicator shall be used, with  
20 the caveat that, When available.

21           And when it's not, then other factors need  
22 to be brought into play such as using mathematical

1 models or breakthrough test data. And all of this  
2 needs to be a part of the respirator program.

3           So in trying to assist our stakeholders in  
4 that effort, we have developed an  
5 end-of-service-life program, and it's a two-pronged  
6 program.

7           The short-term part of that program -- we  
8 thought we could do something relatively quickly --  
9 was in the area of mathematical models. And I  
10 talked to you about this in some detail yesterday.  
11 I will briefly say that currently, breakthrough is  
12 for a single vapor with the effects of relative  
13 humidity. It's available on the OSHA website or  
14 from NIOSH by CD.

15           We are planning later this year to release  
16 multivapor, which will calculate a service time for  
17 a respirator cartridge with five organic vapors and  
18 the effects of relative humidity.

19           And GasRemove is on hold until we are able  
20 to generate some data to support it.

21           Now, in considering an end-of-service-life  
22 program, one of the things we certainly need to do

1 in the sensor area is consider the certification  
2 criteria.

3           And if we look at the NIOSH certification  
4 criteria, we notice a significant fact. And that is  
5 that a system should alert the user when 90 percent  
6 of the service time has been consumed, and  
7 10 percent remains. So what we are really talking  
8 about is an almost end-of-service-life system.

9           Now, those of us who have worked in the  
10 area of industrial hygiene, we think we have seen or  
11 heard all of the horror stories, a new one pops up.  
12 Here's one that is rather interesting.

13           An individual working for a manufacturing  
14 company wears his respirator religiously for seven  
15 years. At that point in time, the company decided  
16 to send him to a training class.

17           And the individual was looking over the  
18 schedule of topics and put up his hand and said,  
19 Excuse me, but I see there is a topic here called  
20 change-out schedules. Does that mean these  
21 cartridges don't last for the life of the  
22 respirator?

1 Well, we think that if we hang some  
2 electronics on with flashing lights, it will cause  
3 some interest in the user to inquire as to what  
4 that's about and hopefully pay more attention to  
5 changing out the cartridges.

6 I have included this slide to give you  
7 some idea of the complexity we are dealing with when  
8 we are looking at multiple solvent assault of an  
9 organic vapor cartridge.

10 In this case, this is an actual cartridge  
11 which we have assaulted with approximately 400 parts  
12 per million of three compounds. You see the arrow  
13 pointing to the concentrations, the assault  
14 concentrations. In this case, we had acetone,  
15 trichlorethylene, and xylene. And the interesting  
16 thing about this is the fact that we get  
17 breakthrough first with acetone, and then  
18 trichlorethylene, and then finally xylene.

19 But as we see here, we are good for the  
20 first 50 to 60 minutes. And then acetone breaks  
21 through. But its ultimate concentration is almost  
22 twice that of the assault concentration. And that's

1 true also of the trichloroethylene.

2           So it becomes quite a significant  
3 situation to not only model and calculate, but also  
4 to develop a sensor system to handle.

5           This slide indicates the concept that we  
6 put forth in attempting to produce an  
7 end-of-service-life electronic system.

8           It's one in which we place multiple  
9 sensors inside the bed. And as the wave -- as the  
10 wave of solvent comes through the cartridge, it  
11 effects a response by the sensor. That information  
12 then is transferred to the user in some form, in  
13 this case, multiple LEDs flashing.

14          Back in 2005, May, we did an external peer  
15 review of our sensor program. And we had seven  
16 external reviewers come in and evaluate it. They  
17 represented regulatory agencies, user groups,  
18 respirator manufacturers, and sensor experts.

19          And the recommendations that came out of  
20 that were essentially to continue our interaction,  
21 our work with CMU, on sensor development, but also  
22 to expand the experimental program to include the



1 effects of sensor placement, temperature, relative  
2 humidity.

3           And we came away with a warm and fuzzy  
4 feeling about that because those were actually the  
5 initiatives that we had included in our research  
6 program. It's just that it hadn't matured far  
7 enough that we were doing that. So they were in our  
8 plans.

9           As a part of that effort to achieve those  
10 things, we built a cartridge simulator, which I have  
11 shown here in a cross-section. It amounts to a  
12 block of aluminum, which you see here on my right,  
13 an example that I brought along.

14           Inside, there's a chamber, an isolated  
15 chamber which we can pack with 50 grams of carbon.  
16 We can also place a sensor at most any location  
17 inside the carbon bed, as well as some external  
18 measurement devices where we can measure  
19 temperature, humidity, and, in this case, using a GC  
20 probe to confirm the concentrations that the sensor  
21 would see.

22           This is an animation of assembling the

1 cartridge simulator with the various components.  
2 The green part you just saw go in was the sensor.  
3 The black was the carbon bed, and then finally the  
4 retention.

5           This is the inside of the simulator  
6 showing the carbon retention material at the bottom  
7 with a sensor being located here in the center and  
8 our GC probe here on the side extending to the  
9 center near the sensor location.

10           Here we have a loading of the various  
11 steps in the cartridge simulator.

12           First we have showing the sensor exposed,  
13 a bed of -- a partial bed of carbon being placed in  
14 the simulator. The second slide shows the sensor  
15 being fully covered. And, finally, the capping with  
16 the fine screen to prevent leakage of carbon out of  
17 the simulator.

18           And down here in the corner, you can see  
19 the actual sensor board and the retaining ring  
20 that's used to secure the sensor system as well as  
21 the carbon bed.

22           Here we have some information we have

1 generated from the simulator. I thought one of the  
2 important characteristics of the simulator should be  
3 that it passed NIOSH certification for a respirator  
4 cartridge, organic vapor respirator cartridge.

5           And, in fact, it does because at the  
6 conditions we run here, using a thousand parts per  
7 million carbon tetrachloride, the 50 grams of  
8 carbon. Air at 32 liters a minute at 50 percent  
9 relative humidity, we should have a breakthrough of  
10 at least -- or a service time of at least 25  
11 minutes.

12           Well, in this case, without the sensor, we  
13 get 96 minutes. And with the sensor, we have got 75  
14 minutes.

15           So what we see here, we are certainly well  
16 within the NIOSH certification requirements. We see  
17 some diminution in performance as a result of the  
18 sensor. That's most likely due to its size and thus  
19 displacement of carbon in the bed.

20           Here's another chart showing the simulator  
21 data with the GC probe simultaneously. What we have  
22 done here is located the GC sampling probe at the

1 center of the bed, midway through it, at half  
2 height, and also collected data at the very end of  
3 the bed.

4           And the idea here is to demonstrate that  
5 we can get adequate data from the center of the  
6 carbon bed.

7           And interestingly enough, the service time  
8 for the full bed is 88 minutes in this case, again,  
9 at a thousand parts per million carbon tet, 32  
10 liters and 50 percent relative humidity. While we  
11 are starting to see what would be defined as  
12 breakthrough for five parts per million at the  
13 center of the bed at 44 minutes.

14           It turns out in this case, it's exactly  
15 half, but that's not always the case. It does very  
16 little.

17           One of the other questions that commonly  
18 is raised is what about the relative humidity  
19 effects on the carbon bed.

20           So here I have got a plot showing the  
21 carbon in the -- packed in the simulator. Again, 50  
22 grams. And we are exposing it to 75 percent

1 relative humidity gas stream at 30 liters per  
2 minute.

3           And what you can see here at the  
4 beginning, the carbon actually reduces the level of  
5 humidity in the exiting gas stream significantly.  
6 We dropped from 75 down to around 30. And we hold  
7 there for approximately 500 seconds. And then  
8 suddenly, we begin to get a rise in the relative  
9 humidity at the exit of the carbon bed.

10           But it doesn't go up to the 75 percent  
11 immediately. In fact, it rises somewhere around 50,  
12 55 percent, and then asymptotically approaches the  
13 75 percent over hours and hours. So it's a very  
14 slow process.

15           But we do see this significant change  
16 occurring early on, and then a leveling off.

17           So we think we can work with that in our  
18 sensor system because we hopefully will just see  
19 this as a baseline shift, this area here as a  
20 baseline shift in the sensor response.

21           One of the other interesting pieces of  
22 data we have gleaned from the cartridge simulator is

1 the temperature effects, and, in this case, the  
2 temperature effects caused by subjecting a carbon  
3 bed to relative humidity.

4           And you can also get temperature changes  
5 in the bed when you add an analyte because there is  
6 the heat of absorption, and that typically is an  
7 exothermic process.

8           Well, in this case, we started out by  
9 subjecting a bed of carbon, again, 50 grams, to an  
10 airstream of approximately 25 and a half degrees  
11 centigrade and relative humidity of about  
12 30 percent.

13           And we continued to run that, let it  
14 equilibrate for about 20 minutes, and then jacked up  
15 the relative humidity to 80 percent. And you can  
16 see we get a significant -- I'm sorry, 60 percent.  
17 We get a significant rise in temperature of almost  
18 four degrees, and then it begins to diminish.

19           We left it run for a short period of time,  
20 and then added a gas stream of 80 percent of  
21 relative humidity. And you can see we got another  
22 temperature rise.

1 Continued on for a short time, began to  
2 see a diminution in temperature and then reduced the  
3 relative humidity to gas stream to 30 percent. And  
4 we see a significant drop off in temperature.

5 Now, at this point, we said, Well, let's  
6 see what adding an organic contaminant to the gas  
7 stream does. In this case, we added a couple of  
8 hundred parts per million isopropyl alcohol. And as  
9 you can see, we got a significant rise in  
10 temperature of the carbon bed. And when we turned  
11 the alcohol off, we began to see a diminution of  
12 temperature back to a normal ambient.

13 Obviously, temperature is a factor, and  
14 variations in temperature is a factor when you are  
15 attempting to place sensors inside the carbon bed.

16 This is a breakdown of our sensor system  
17 that we are currently using in the cartridge  
18 simulator. It consists of a silicon chip with six  
19 sensors on it. You see the six here that I'm  
20 identifying with the arrows, three of which are  
21 exposed to the environment and three are covered to  
22 protect it from seeing things like the organic

1 contaminant.

2           What we think we can do with this is by  
3 incorporating a four-way bridge, is to use those  
4 covered sensors to subtract out backgrounds such as  
5 temperature and noise.

6           The sensors consist of a spiral electrode  
7 arrangement. Looks similar to a burner on your  
8 electric stove, which you have got gold electrodes  
9 in a spiral fashion with a three-micron gap between  
10 those.

11           This entire section you see here, which is  
12 representative of the sensor over here, is a hundred  
13 microns in diameter.

14           And onto that, we jet a very special  
15 polymer. It has some unique properties in that it's  
16 a conductive polymer. This polymer series is called  
17 polythiophene, unique in that it is a polymeric  
18 conductive material as opposed to most polymers,  
19 which are insulators.

20           This is a cross-section of how that sensor  
21 is constructed.

22           It starts out on a silicon wafer, you see



1 at the bottom. Onto that is a surface of 500  
2 angstroms of silicon dioxide. And plated onto that  
3 is 20 angstroms of titanium. And finally onto the  
4 titanium is deposited 600 angstroms of gold.

5           The reason for the bimetal system is  
6 because gold doesn't adhere well to silicon dioxide,  
7 but titanium does. So we use the titanium as the  
8 initial layer to adhere the gold, which is our final  
9 topical layer that we are very interested in.

10           Then onto that, we use an inkjetting  
11 process, similar what you would use in an inkjet  
12 printer to deposit microdroplets of these  
13 polythiophenes, which I just explained to you about  
14 being a conductive polymer.

15           You also see these wells on the side  
16 labeled SU8. Those are simply supports that are --  
17 polymeric supports that are built up for supporting  
18 the cover plate.

19           And then all of that is contained in a two  
20 and half millimeter by two and a half millimeter  
21 silicon wafer that we then wire bond to the outside  
22 world.

1           It is placed in a TO-5 panel, which is a  
2 very common electronics package used in the  
3 electronics industry. The sensors are bonded from  
4 these bond pads to connections on the TO-5 package  
5 by 50-micron gold filament wire. You may be able to  
6 see some of those here on the sides.

7           As I said earlier, the entire package is  
8 approximately a quarter of an inch in diameter.

9           That then is capped, again, with the TO-5  
10 package. And we have a hole in the center for our  
11 gases to enter into the system. That is then  
12 covered with Gore-Tex to help us get some additional  
13 filtering.

14           We use the Gore-Tex to help us prevent  
15 carbon fines from getting into the sensors. Since  
16 the carbon is conductive, that would be a problem,  
17 getting those in contact with the sensors. We also  
18 use it to inhibit some of the transfer of moisture  
19 into the sensor system.

20           And then this entire package is covered  
21 and placed inside the cartridge simulator.

22           And finally, I thought I would include

1 some data showing the response of the sensor system.

2           In this case, we started out with a bed of  
3 carbon, not the simulator in this case, but a bed of  
4 carbon in which we got a baseline, then began adding  
5 isopropyl alcohol to the point that we started to  
6 see breakthrough in the bed.

7           And this then is the sensor response that  
8 we see. And finally, when we turn the IPA off, the  
9 isopropyl alcohol, we saw a diminution in sensor  
10 response. So it did give us a warm and fuzzy  
11 feeling that we in fact could get a response from  
12 organic breakthrough.

13           While the system I have talked to you  
14 about now looks a little cumbersome, it's not our  
15 ultimate goal. Our ultimate goal would be to take  
16 the sensors you have seen, add the electronics to  
17 it, put that all into a single chip package, and add  
18 an antenna.

19           Reduce that about the size of a carbon  
20 particle so we could then distribute those  
21 throughout the bed of the cartridge. And having an  
22 antenna on it, we could then transmit RF power to

1 it, poll the sensor, take some readings, and have it  
2 transmit information back to a central processing  
3 unit. This would all be done wirelessly. That  
4 information then could be fed in some format to the  
5 user, either in the form of LEDs or a digital  
6 display.

7           Back in 2004, we did place an announcement  
8 in the Federal Register asking for companies,  
9 manufacturers who would be interested in partnering  
10 with us to come forward and work with us on the  
11 integration of sensors into respirator cartridges,  
12 and these were the companies that volunteered to  
13 work with us.

14           We also sent that same notice out to our  
15 electronic mailing list. And, again, these are the  
16 companies that responded.

17           And we expect to be working with them in  
18 the first quarter of 2007 on actually integrating  
19 sensors into the cartridges for testing purposes and  
20 evaluation because we think that integration is a  
21 major part of this program.

22           Back in June, we released a sensor program

1 newsletter that we intend to continue. This was  
2 done via the electronic mailing list. So if you  
3 didn't get that, and you would like to have it in  
4 future versions, which we do expect to send out as  
5 we have significant developments in the program,  
6 please get your name on the list so you can get a  
7 copy.

8           And finally, while I have been talking  
9 today specifically about the respirator application,  
10 the idea here is to produce a sensor system that's  
11 capable of being utilized in personal protective  
12 equipment in general. And we think this application  
13 has that capability.

14           So with that, I will open it up to any  
15 questions you might have.

16           MR. SPAMPINATO: Is this on? You showed a  
17 slide -- Phil Spampinato, ILC Dover.

18           You showed a slide where you mentioned  
19 that the sensor lowered filter performance, and I  
20 think that slide was something like 20 or  
21 25 percent, and there was other information there,  
22 and you had a comment about it.

1           But do you see an inherent lowering of  
2 filter performance because of the presence of either  
3 the sensor or the chemicals involved here?

4           MR. SNYDER: Given our current  
5 configuration, yes, I do see a lowering occurring.  
6 However, that's not our ultimate configuration.  
7 These are really only experimental devices at the  
8 moment. They are large.

9           Our next iteration of this will be  
10 significantly less.

11          MR. SPAMPINATO: Thank you.

12          MR. SELL: Bob Sell, Draeger Safety.

13          Have you done any conditioning tests to  
14 look at the reliability of the sensor in the system?

15          MR. SNYDER: No. We haven't gotten to  
16 that point yet. We are just getting sensors to the  
17 point that we can collect data in this format.

18          Once we are comfortable we can do that and  
19 reproduce it, we will be doing things like that.

20          MR. HEINS: Bodo Heins, Draeger Safety,  
21 Germany.

22          To point the same out what Bob just said.

1 All these methods you have seen here, or you showed,  
2 very, are very good for laboratory measurements of  
3 such things, but I invite you to come to see how a  
4 canister cartridge is be done. It is something  
5 which happens in seconds.

6           How will you fit all of this stuff into  
7 the cartridge or canister? And the biggest question  
8 then is who has to pay for that.

9           It's everything which is thrown away  
10 afterwards.

11           MR. SNYDER: Well, let me comment on that.

12           I would like to work with the volunteer  
13 companies that we have got.

14           MR. HEINS: Yes. But are we waiting one  
15 and a half year already. We are rather disappointed  
16 that it is going so slow because it is a very  
17 important topic, but you have to follow your --

18           MR. SNYDER: We share that disappointment.

19           MR. HEINS: One of the major questions  
20 which has to be solved before is, Who is responsible  
21 for an accident which happens? Because a number of  
22 possibilities, what should have gone wrong.

1 First is that the sensor was wrong. It  
2 was wrong calibrated. The user didn't notice what  
3 the sensor showed, and a lot of other possibilities.

4 The biggest one probably in this case is  
5 that your sensor afterwards are different  
6 measurements. They are reversible. So if something  
7 happen, you cannot find out what that test time of  
8 the emergency case happened with it.

9 So, you know in your country, this can be  
10 very expensive.

11 MR. SNYDER: We recognize those issues,  
12 and we agree that they are important. But we think  
13 that we need an operable system first before we can  
14 those issues.

15 MR. HEINS: Okay. And I understood right  
16 that you at this time only had for OV, or at a  
17 maximum four or five OV gases sensors available.

18 MR. SNYDER: Yes. We have only been  
19 working on OV.

20 MR. HEINS: Because my concern is that  
21 it's much more interesting or important that we, for  
22 example, if you look to the CBRN topics, for this



1 types, for to have something.

2 MR. SNYDER: One of the virtues that we  
3 really like about this sensor system that we have  
4 been working out with CMU is its versatility. It is  
5 a multiple modality system. We are not locked into  
6 just a chemo resistant device.

7 So we think it will be capable of  
8 expanding to other agents that are not organic.

9 MR. HEINS: As far as I understood, your  
10 reactions here, chemical reactions at this time only  
11 possible for OV, and I have no idea if you have  
12 already something against other stuff, like gases or  
13 vapors.

14 Okay. But one very important point is the  
15 90 percent requirement.

16 I think this is a requirement from the  
17 past which you have to think over. As I said some  
18 minutes before, the sensor will measure everything  
19 of what is going on actually, and that it doesn't  
20 stop at one time.

21 So and to show when 90 percent is done,  
22 that belongs also to the environment or the

1 conditions around. And if it changes something,  
2 then it immediately has to show something different.

3 MR. SNYDER: I think we need to  
4 demonstrate that we can't (sic) meet our  
5 requirements first. And if, in fact, that is the  
6 case, then we visit a requirement such as  
7 certification.

8 MR. HEINS: Did you ever calculate the  
9 costs for such an equipment? Not only the sensor,  
10 but you also need the measurement unit, too.

11 MR. SNYDER: Yes. One of the  
12 considerations that we have continued to have  
13 throughout this development program is to attempt to  
14 keep sensors under a dollar, and the electronics in  
15 the 20 to 50 dollar range with the electronics being  
16 reusable and the sensor being considered disposable.

17 MR. HEINS: For each canister? The cost  
18 for each canister?

19 MR. SNYDER: A dollar for the sensors for  
20 canister. But the electronics would be associated  
21 with the facepiece and removable so that they would  
22 be reusable.

1           MR. HEINS: But for one mask and one user  
2 only, so you need to have a lot of additional  
3 equipment.

4           And what is going on with the twin filter  
5 system? Do you need to have two of those things?

6           MR. SNYDER: No. We think the electronics  
7 will be such that it can monitor both cartridges,  
8 for example, if you have a two-cartridge system.

9           MR. HEINS: And another point which is  
10 going into the cost is that this sensor needs to be  
11 calibrated, and I guess this calibration will be  
12 only valid for a limited time. And I expect much  
13 less than the storage time of the canister.

14           It will reduce the storage time of  
15 canisters in this case and makes this, again, much  
16 more expensive.

17           MR. SNYDER: Again, a very good point.

18           We need to look at storage and aging of  
19 these devices to determine what the effects are.

20           I can't answer that question yet, but it's  
21 obviously a very important issue.

22           MR. HEINS: Okay.

1 MR. SMITH: Thank you. Simon Smith, 3M  
2 Canada.

3 You showed the effects of the humidity and  
4 additional solvent on the temperature.

5 I just wondered if your mathematical  
6 models are using -- take into account those  
7 temperature changes.

8 MR. SNYDER: Yes, it does.

9 Well, you -- in the model, you have to put  
10 in the ambient temperature.

11 MR. SMITH: The ambient, yes. But then  
12 the elevation, is that taken account of?

13 MR. SNYDER: No. That's handled by some  
14 other factors in the equations. Essentially, we  
15 have used Weaver (phonetic) equation, added some  
16 palangi (phonetic) potential theory to derive those.

17 MR. SMITH: Yes. Thanks. I think those  
18 were my only concerns. Thanks.

19 MR. VINCENT: John Vincent, North Safety  
20 Products.

21 Has any market research been done on what  
22 users, or premium users would pay for this kind of

1 technology? And, if so, could you share that with  
2 us? Premium and price, what they would pay for  
3 cartridges and these electronics for the facepiece.

4 MR. SNYDER: Yes. We had a research road  
5 map document developed for us several years ago by  
6 the Naval Research Lab, and we chose them because  
7 they had extensive experience in sensor development.

8 But they looked at various aspects, talked  
9 to user groups, respirator manufacturers, and so  
10 forth, and did come to some conclusion on cost.

11 And that was that an order of \$2, 2.50  
12 additional on a cartridge would be acceptable.

13 MR. SAVARIN: Mike Savarin, Bullard  
14 Technology, or just Bullard now.

15 I just want to say something on behalf of  
16 maybe the group. As someone now looking on the --  
17 on the outside looking in, I think this all looks  
18 quite fantastic, the latest technology, new way of  
19 thinking about going about some of the issues.

20 From my perspective, I think it is  
21 extremely encouraging, although some of the  
22 commentators have obviously made it clear that has

1 taken quite some time, which is in my opinion is no  
2 surprise.

3           The group, of course, is going to want to  
4 consider when are they going to get something real,  
5 are real effects considered, and how much is it  
6 going to cost.

7           Yet the fact is we can't be anywhere near  
8 something practical in terms of costs yet. So I'm  
9 not quite sure why we are all hammering and thinking  
10 about how much the cost is going to be when it is  
11 pretty clear that -- what generation are we in now?  
12 I don't know if it is the fifth.

13           MR. SNYDER: Yes. In fact, the fifth has  
14 just gone to the foundry.

15           MR. SAVARIN: So it's looking like a few  
16 away yet from all of these facts that people are  
17 considering.

18           So I want to thank the group for letting  
19 me have an insight into what some of the critical  
20 aspects beyond what is some of the technology that  
21 you have proposed and put forward in your work  
22 today.

1 Thanks.

2 MS. FEINER: Lynn Feiner, North Safety  
3 Products.

4 In the real world, cartridges are not used  
5 continuously, but they will be used for an hour.  
6 Then they may be put away for a couple of days and  
7 used for a couple of more hours.

8 And have you taken that into  
9 consideration, and are you working that into your  
10 models?

11 MR. SNYDER: Yes. Interesting you bring  
12 that up because we do have a program this year which  
13 we are calling an extension of the multivapor model,  
14 which we are looking at just that aspect of it, that  
15 is people utilizing for a period of time. Then you  
16 have an interval of nonuse and reusing them again.

17 So we are attempting to do something about  
18 that in terms of our modeling program.

19 MS. FEINER: And when you are looking at  
20 organic vapors, are you looking for an organic vapor  
21 family rather than for specific organic vapors?

22 MR. SNYDER: In the modeling?

1 MS. FEINER: Yes.

2 MR. SNYDER: No. It's for an individual  
3 compound.

4 MS. FEINER: Okay.

5 MR. SNYDER: In fact, the models have a  
6 library of about 1,400 compounds of data in there,  
7 so you can go in, identify a compound, either by its  
8 IUPAC name or its common name.

9 And you can then locate data which you  
10 need to plug into the model for it, such as  
11 molecular weight, the vapor pressure, et cetera,  
12 polarizability.

13 MS. FEINER: Okay. Thank you very much.

14 MS. DEMEDEIROS: Edna DeMedeiros, North  
15 Safety Products.

16 Jay, I'm wondering in your experiments,  
17 okay, have you done what Lynn was saying where you  
18 take the cartridge, you expose it to chemicals.  
19 Then you put it away. Then you take it again,  
20 expose it to chemicals, put it away.

21 What's the effect on the sensor?

22 MR. SNYDER: Can't answer that yet. We



1 haven't done the experiments yet.

2 MS. DEMEDEIROS: So you're not to that  
3 point yet.

4 MR. SNYDER: That's correct.

5 MS. DEMEDEIROS: And your models that you  
6 are discussing, those are basically based on Jerry  
7 Wood's work?

8 MR. SNYDER: Yes.

9 MS. DEMEDEIROS: All right. Okay. Thank  
10 you.

11 MR. SNYDER: Okay. Last question.

12 MR. HEINS: Bodo Heins again.

13 You should point out what's the main  
14 purpose of this end-of-service-life indicator,  
15 should be -- is it for the user to be -- to get a  
16 warning when he has to go out, or is mainly as the  
17 first end-of-service-life indicators has been a  
18 topic for the employer, that he knows when he has to  
19 buy new cartridges.

20 Okay.

21 MR. SNYDER: It's designed to protect the  
22 employee.

1 MR. HEINS: And another --

2 MR. SNYDER: In a couple of ways.

3 As I mentioned, hopefully with having  
4 something obvious like this in the system, it would  
5 generate more interest in finding out what about  
6 change-out schedules and what about changing your  
7 cartridges, but the bottom line is to provide  
8 additional protection to the user.

9 MR. HEINS: Okay. And the last remark  
10 again to the environmental conditioning.

11 If you place these sensors inside the  
12 charcoal bed, what is obviously the case here, the  
13 canister will no longer be vibration tight, and this  
14 is a requirement.

15 If you have cable, it's more difficult.  
16 If you have no cable, the sensors will move inside  
17 the charcoal bed.

18 So have a look to the vibration tightness  
19 or -- approval for the canister if you would fit  
20 your canister -- your sensors in. Excuse me.

21 MR. SNYDER: Good point. I appreciate you  
22 bringing that to our attention.

1           That's obviously a point that we should  
2 take into account as we are looking at the  
3 integration of these sensors into cartridges.

4           MR. SHAFFER: Let's thank Jay for his  
5 excellent presentation.

6           And I hope we fixed the automatic fast  
7 forwarding of the slides. This is why you should  
8 never do a public meeting on Friday the 13th. I'm  
9 convinced of that now.

10          With that, I'll turn it over to Ziqing  
11 Zhuang. He is going to talk about NPPTL respirator  
12 fit test panels.

13          NPPTL RESPIRATOR FIT TEST PANELS

14          MR. ZHUANG: Okay. Yes. Good morning.  
15 First of all, I would like to thank my -- the team.  
16 Dr. Ron Shaffer has been helping me with the PCA  
17 analysis. And then Dr. Bruce Bradtmiller is the  
18 president of Intertek, and he was one of the  
19 principal investigators for the Army survey in '88  
20 and has been in this field for many years.

21          And then also, this is the company that  
22 help Alan Hack develop the Los Alamos panel.

1           And Dennis Viscusi, he also has been  
2 working with me on this project. And also I was  
3 able to get Dr. Ray Roberge to help with another  
4 aspect of the project to look at body mass index and  
5 facial dimension. And then I was able to get some  
6 summer student and also my Ph.D. student to help me  
7 to work on this project.

8           Yeah. We all know that it is important to  
9 have a good fit test panel because they have been,  
10 yeah, relied upon to provide sizing reference for  
11 respirator in many applications. And as soon as the  
12 LANL panel was developed, they were used to do fit  
13 testing on various model respirator. And then those  
14 data were used to establish the first set of APF.

15           And then also, yeah, as I mentioned  
16 earlier, they have been used to develop a  
17 respirator. And then currently we have the Total  
18 Inward Leakage program, and we need this kind of  
19 panel also. Otherwise the testing may not be --  
20 meaningless.

21           And then also various researchers have  
22 used the panel to include subject in the past.

1           Historically, yeah, at that time, back in  
2 earlier 1970, there was no civilian data. And so  
3 the Air Force data was the only data set available  
4 at that time.

5           And then so they cover -- they show that  
6 data was representative of the U.S. adults, and then  
7 face length, face width, and lip length was selected  
8 at that time. There was no scientific basis. There  
9 was no study to look at correlation between facial  
10 dimension at all.

11           And so basically, just use common sense or  
12 follow some of the idea from the Air Force, that  
13 when they designed the oxygen mask, they used lip  
14 length and face length to look at their size.

15           And then there is the LANL panel for  
16 testing full facepiece respirator. And it is based  
17 on face width and face length, and it range from 93  
18 a half to 133 and a half for face length. And then  
19 for face width, it is from 117 and a half to 153 and  
20 a half.

21           And based on -- basically they use the  
22 mean of the male and mean of female subject and just

1 add two standard deviation to the mean of the male  
2 and the mean of the -- and subtract two standard  
3 deviation from the female to come up with the  
4 boundary.

5           And then for the upper lip and lower right  
6 corner, very few subject were there, so they delete  
7 those cells. And that left a 10-cell panel. And  
8 these are the number of the subjects that they  
9 recommend that we should sample from each cell.

10           And this is the one that's for testing  
11 half-mask respirator, and it is based on lip length  
12 and face length.

13           And it is similar. This time, it's not  
14 four column. It's like three column, and only two  
15 cell was deleted. But we still have 10 cells here.  
16 And each of the cells, these are the numbers that we  
17 will sample from each cell.

18           So right after the panel was developed  
19 and, yeah, we would have -- yeah, there was some  
20 concern. And then, but lately, we, yeah, look at  
21 the demographics of the U.S. population. And now it  
22 has changed a lot over the last 30 years. And then

1 also there some evidence that military data may not  
2 represent the diversity that you will see in the  
3 civilian population.

4           And we also have some scientific evidence  
5 as early as like 1975, as I mentioned, there is a  
6 study, like a fit test program that they -- fit test  
7 about like, yeah, 1,467 employee. And while they  
8 are doing the fit besting, they measure the  
9 employee, and they find out there are more than like  
10 12 percent of their subject were outside the LANL  
11 panel.

12           And at that time, they recommend revision  
13 of the panel. And then also, Bureau of Mines in  
14 1978 did a survey of, yeah, 48 male, and they look  
15 at the bivariate distribution of face length and  
16 face width. And they found out it is significantly  
17 different from the LANL panel. So -- and they said,  
18 oh, that's their Cartwright panel for male worker.  
19 And that is a very small sample. But that's what  
20 they claim in their study.

21           And then, yeah, we have various study  
22 later on. One of them is Ken, Dr. Ken Ostenstep

1 (phonetic) at University of Alabama, and I also talk  
2 to him as well.

3           And in his study, he found out lip length  
4 did not have any correlation with respirator fit.  
5 And that's one of the dimensions that Los Alamos  
6 used, but it's not relevant to fit.

7           And then also, lately, we have CAESAR  
8 project. It's called Civilian American and European  
9 Surface Anthropometry Resource. And this is a  
10 project conducted by the US Air Force. And they  
11 have about like 40 comments from different industry,  
12 the aircraft industry, automotive industry, and also  
13 the apparel industry as well.

14           So they -- but what they did was to  
15 measure like civilian American, except they focusing  
16 on whole body. Like they scan the subject using the  
17 whole body scanner, and they only measure like  
18 limited dimension was the traditional measurement.

19           So unfortunately, by the time I know that  
20 they have such a project, they only measure two  
21 dimension, and it was too late to ask them to do any  
22 other measurement, to add any other dimension.



1           So -- but I was able to use the face  
2 length and face width information and to look at how  
3 they differ from the LANL panel. And then at that  
4 time, I found out that like 16 percent of the  
5 subject were outside of boundary.

6           And so with that, we started to create a  
7 database of our own, detailing the face size  
8 distribution of the current U.S. respirator user.  
9 So we went to, like various industry in eight  
10 different state and national survey.

11           So whereas the data, we were able to  
12 confirm that. The Air Force is not reflective of  
13 the anthropometric distribution anymore. And that  
14 paper was published back in 2004.

15           And we also concluded that we need to  
16 revise the panel or come up with new panel.

17           So today I'm just focusing on the  
18 development of the new panel that are representative  
19 of the current US work force.

20           So we used the data that we collected back  
21 in 2003, and that paper was published last year,  
22 November of last year in the JOEH Journal. And we

1 described our study. We published the summary.  
2 statistic for male and female. We also did a  
3 comparison between our data and the military data.

4           And just, you know, confirmed that our  
5 data like, yeah, it represent more diversified  
6 population and different from the military data.

7           So in that survey, we use a stratified  
8 sampling approach.

9           We look at male and female. We have  
10 white, African-American, Hispanic, and other. We  
11 combine Hispanic -- we combine Asian and Pacific  
12 Islander and also Native American into one group.

13           And we also arbitrarily like divide the  
14 population from 18 to 65 into three interval, like  
15 from 18 to 29, to 30 to 44, and 45 to 65. And our  
16 final tally of the database is 3,997 subjects.

17           And we use the 2000 US Census data to  
18 weight our subject, to match the U.S. adult, like 18  
19 to 65. Then we -- so our estimates covered national  
20 estimate also. And at that time, we used  
21 traditional tools to measure 19 dimensions, and then  
22 we also scanned one-fourth of the subjects.

1           So the approach that we are using to  
2 develop the new panel, the first one is just we  
3 still use two dimensions, which is called bivariate  
4 distribution, and the other one is principal  
5 component analysis.

6           Yeah, the bivariate panel has been  
7 developed since like 2004, so it has been around for  
8 a while. But the PCA panel, it's the first time --  
9 the first word is different, and now we kind of,  
10 yeah, keep on changing it and revising it.

11           And the criteria for selecting the  
12 dimension, the approach that we use is like it needs  
13 to be relevant to respirator fit. And what we can  
14 do is, now, it's not like '70 anymore. So we do  
15 have 30 years of information that -- eight study out  
16 there look at.

17           So we did the literature review, and we  
18 also talk to the expert, the ISO committee, the  
19 manufacturers. And so based on that kind of  
20 information.

21           And for -- we selected the two dimension  
22 for the bivariate panel. But for the PCA, we add

1 some more criteria.

2           We think that if the dimension you exclude  
3 and can be well predicted by the other one that you  
4 include, then that will be good. So you cover the  
5 facial characteristic very well.

6           And the number of -- the dimension is --  
7 also, originally, you do all the measurement, and  
8 some of them are a little difficult to measure. You  
9 need to pressure the hair a little bit. You get a  
10 small number. Or if you don't press that much, you  
11 may get a larger number. And there are a lot of  
12 dimension that we try not to use, and select the one  
13 that we can measure with a little bit of accuracy.

14           And so the dimension -- yeah, this is the  
15 principal component analysis, and -- yeah.  
16 Principal component analysis defines a new  
17 coordinate system using linear combinations of the  
18 original variables to describe trends in our data.

19           And for our data, you may see that, like  
20 the subject on the left, after you finished  
21 analysis, you can identify which subject as small or  
22 they are large or they in the middle, or medium, or

1 maybe short and wide, or long and narrow.

2           So based on the literature review, we also  
3 look at our own study between fit and facial  
4 dimension also. And so we publish another paper  
5 there to report our finding and also summarize what  
6 people found in their studies.

7           And then also, at the ISO committee, the  
8 committee also look at this kind of things, and they  
9 said -- they also look at -- select dimension, what  
10 dimensions should be looked at or should be  
11 selected. And so -- and then -- so at that time, we  
12 think that lip length may not a good dimension to  
13 use.

14           And so the bivariate panel, we still keep  
15 10 cells, and the 25 subject. We did not address  
16 that. Just keep whatever Los Alamos used at that  
17 time.

18           And then what we did was that we tried to  
19 make sure that at least two subjects for each of the  
20 cell. And then the real of the cell, like you want  
21 to match the population, the distribution of the  
22 population to your sample size as much as possible,

1 and then face length and face width were selected to  
2 define the bivariate panel in which may be used for  
3 both half-mask and full-facepiece respirator.

4           And this is the new panel. And you can  
5 see the range is quite different from the Los Alamos  
6 panel. It range from 98 and a half to 138 and a  
7 half, and 120.5 to 158.5. And then we kind of label  
8 them from one, two, three, four, five, six, seven,  
9 eight, nine, and 10. And these are the subjects  
10 that we recommend that you, yeah, can select from  
11 each of the cell.

12           I think they are all two subjects except  
13 Cell No. 4, where you come in five, and Cell 7,  
14 where you come in four person.

15           And this other percentage that we  
16 estimated for the population work force, whatever  
17 you want to call it, we don't have any profile like  
18 how many male, female for respirator user. We don't  
19 know how many like -- like each -- in each group, we  
20 didn't have that.

21           So all we can tell is like we can get the  
22 national statistic and then the work force, the

1 users group. They do it different from that. So  
2 that's our estimate.

3           And it's -- yeah, the results are  
4 25 percent of the population are in Cell 4, and Cell  
5 7 is 21.3 percent.

6           And based on that, that's why those two  
7 cell we recommend sampling more subject. And then  
8 the rest of the other cell have a range from 3.5 to  
9 10.5. And so even some of them are larger than the  
10 others, we still recommend that it's important to  
11 sample at least two subjects from each of the cell.

12           And this is the scatter plot of the data  
13 of the subject that we have. And we still have some  
14 people with wider face. Our data, we cannot  
15 include. And we only -- but the panel does cover  
16 more than 95 percent of the population.

17           And these are the dimension that we use  
18 for the principal component analysis.

19           And, again, like this is the dimension  
20 that we use like based on the criteria that I  
21 mentioned earlier.

22           We look at literature review. We look at

1 expert opinion. We look at correlation analysis.

2           And these are the nine dimensions that we  
3 do not use. And then -- but they can be predicted  
4 by the 10 dimensions that we included in the PCA  
5 panel, with an R square of like .83 for maximum  
6 frontal breadth and p-value for that is .01.

7           So the one with the smallest R square is  
8 bitracion coronal arc, which is the one going above  
9 and then come down to the -- on the other side. And  
10 that's the one that I -- yeah, we think that is  
11 highly variable, and it's a little bit difficult to  
12 measure and may not be that related to respirator  
13 fit also. So this are the kind of dimension that we  
14 can exclude.

15           And this is the results. We run the  
16 principal component analysis. Back in the '70s, if  
17 you want to do this kind of analysis, it may take  
18 you a year or so. But now computer can do it for  
19 us, and quickly, just, yeah, several seconds or one  
20 minute or so, you can get the results.

21           And we included 10 dimension. We can also  
22 get 10 principal components, and that's the



1 analysis.

2           And then we have a set of eigenvalue. And  
3 then the cumulative is like just add whatever like,  
4 yeah, of the eigenvalue for each of the component,  
5 and then we have a total -- like percent of total  
6 variance, each component can explain. And then we  
7 can also calculate the cumulative also.

8           So and then one of the rule of thumb is  
9 like the eigenvalue. If it's less than one, you  
10 should not look at those component anymore. And  
11 that's one of the purpose to do the principal

12 component of analysis.

13           Basically you can look at less variable,  
14 but then it can explain most of your variation and  
15 then do whatever you want to do with that.

16           And at this point, we -- early on, the  
17 earlier version of the PCA panel, I look at three  
18 dimension, and I think that's too complicated to  
19 use. And so we kind of scale back. But if we use  
20 this type of rule of thumb based on our -- like  
21 sadisco (phonetic) test or -- so we kind of decided  
22 to keep two principal component only.

1           And then these are the eigenvector, which  
2 is kind of -- a set of coefficients. And one is  
3 like PC1 is a bunch of original measurement, all the  
4 ten dimensions times the corresponding coefficient.  
5 And the sum is that score for that particular  
6 person.

7           And then PC2 is different, like it -- so  
8 the first one, they are all positive. And so the  
9 larger the dimension, the larger the PCA score,  
10 that's why you may have from small to large.

11           But the second one, sum of the  
12 coefficient, the loading, lateral loading, like  
13 .3598, these are the significant ones, very  
14 important, but then they are positive.

15           Like face length, nose protrusion, they  
16 are positive. That means like if face length is  
17 longer, PCA2 is larger also. And then -- but on the  
18 other hand, we have some negatives. That means if,  
19 like the face width or bigonial breadth or  
20 interpupillary breadth, like these are the  
21 dimensions of -- like the wider, the smaller the PC2  
22 component.

1           So when you look at that figure or the  
2 distribution, the people on the left tend to be like  
3 the first principal component, they are small, and  
4 then it go to medium and large.

5           But then if you look at the vertical,  
6 Y-axis, the second principal component, then the  
7 people at the bottom, the smaller PCA2 variable,  
8 then they are wide.

9           They have wider face and then wider nose  
10 and then shorter face as well. And when the people  
11 on top, they are kind of opposite. They tend to  
12 have longer face and narrow nose. And so this is  
13 based on the distribution of our data.

14           This is the new principal component  
15 analysis panel.

16           And so the ellipse cover about 95 percent  
17 of the population, and the standard smaller ellipse  
18 cover about 35 percent of the population. And that  
19 can be changed.

20           Like some people recommend up to 50, and  
21 also some people say like a medium size can fit can  
22 fit 70 percent of the population.

1           So but at this point, from a sampling  
2 approach, you can do whatever you want.

3           And, basically, we, yeah, divide the  
4 ellipse into four area, like one, two, three, four.  
5 And in the middle, it's the same things. And so we  
6 have eight cells. And these are the estimate of the  
7 population in each of the cell.

8           And you can see the total column. Like  
9 14.7 for Cell 1. They are all very uniform, around  
10 15 percent. And in the middle like, five, six,  
11 seven and eight, it's about an 8 percent or 9  
12 percent.

13           So the total is like 96.8. And these are  
14 the kind of number of subjects that we recommend to  
15 sample. And, again, this is a number that we do not  
16 do any statistical analysis to come up. We just  
17 keep on using the same number that has been used in  
18 the past.

19           So we did some comparison of the two  
20 panel. For the bivariate panel, it is very easy to  
21 understand and use. And since we came up with this  
22 panel, 3M already recruited subjects. And they were

1 able to put together two panels, identical, like all  
2 25 subjects, and then all together 50 person.

3           They also did some fit testing on the  
4 data -- on the subjects. So it's very easy to use,  
5 and they only measure about a hundred people of  
6 their employee.

7           And then for our own TIL testing, we  
8 measure about 146 subjects. And most of them -- we  
9 used 87 of them. But then they are all one way --  
10 like -- in one of the cell. And we excluded about  
11 4.7 percent of the subject.

12           And so very easy to recruit subject.

13           And then, yeah, like in comparison with  
14 the LANL panel, like when I look at our subject,  
15 like 146 subjects, I did not see any subject. Like  
16 if you use lip length and face length, I did not see  
17 any subject in Cell 1, 3, and 6 of the LANL panel,  
18 and only one subject in Cell 2.

19           So from that, it kind of like validate the  
20 development of the panel here based on just a couple  
21 of the sample, like our own subject, and then the  
22 subject in 3M.

1           But then the bivariate panel may not  
2 exclude end user faces, like -- because you only  
3 look at face length and face width. And so someone  
4 has a larger nose, then you may still include that  
5 subject, or you don't consider that characteristic.

6           But then we did use our database. We also  
7 did a simulation to measure how many subjects you  
8 need to measure to fill the panel.

9           And on the average, like we get 91  
10 subjects. It range from 34 to 264.

11           And then for the PCA, on the other hand,  
12 it is complicated and more measurement, 10 versus 2,  
13 but it's very like to include unusual face. You  
14 look at -- it's extremely long, extremely large, or  
15 very short nose. Those are the people that like,  
16 yeah, you can exclude them.

17           And then from our simulation analysis, you  
18 only need to measure 58 subjects to come up with the  
19 25-subject panel. And the minimum of subject to  
20 measure is 28, but you can -- you have to measure as  
21 many as like 144 to fill the panel.

22           And so another advantage of the PCA is

1 like dimension including the model correlated with  
2 those excluded, too.

3           So at this point, we have developed two  
4 panel. And respirator designed to fit this panel, I  
5 expect it to accommodate more than 95 percent of the  
6 current US civilian work force. And both panel  
7 represent an improvement over the LANL panel used  
8 today. And it's up to the certification body or  
9 standard to select which one to use.

10           And this is, yeah, future follow up.

11           Right now, we are looking at differences  
12 among age or race and gender. And we also would,  
13 yeah -- in fact, I did some comparison study between  
14 the bivariate and PCA using the TIL data. And I was  
15 able to -- they all fit the panel, even the slide  
16 that Doug showed yesterday, scattered a lot. But if  
17 you look at a smaller -- like you group some of the  
18 cell, you can see very good pattern, particular for  
19 PCA.

20           Like if you have a large respirator, it  
21 tend to fit the people in the large cell. And then  
22 for small or medium, like we can see good pattern

1 there except all you do is counting. And we have a  
2 hundred more, and I can count maybe most of them.  
3 And it's kind of like not a statistical test, and I  
4 do not -- we need more discussion to make any valid  
5 conclusion there.

6           And then, on the other hand, we also do  
7 some headform using our three-dimensional data. And  
8 then the picture on the, yeah, right is our first  
9 generation of headform.

10           And so this is one individual from the  
11 medium. But then it is just too much like  
12 individual. So right now, we are looking at the  
13 second generation, trying to average them.

14           So average the dimension for the people in  
15 each of the cell based on a certain like sizing  
16 scheme, and then pick the one that are close to the  
17 average. And then -- and then maybe average a few  
18 subjects.

19           So by the end of the averaging, then we  
20 do -- that headform will not be a single person. It  
21 will be more representative a group of people.

22           And then we also have a study in China



1 that was that was like sponsored by, yeah, seven  
2 manufacturers, and, yeah, it was last year. And  
3 then we have finished the data collection and are  
4 doing some analysis right now.

5           And then in the lab, we also look at  
6 respirator fit, and we are also trying to measure  
7 three-dimensional parameter and see would that be a  
8 better prediction of respirator fit.

9           So this is a summary of what we have  
10 published, and then one is in the queue right now.  
11 It has been submitted.

12           So, again, each one document -- each of  
13 the step, that what we did, and address particular  
14 question scientifically.

15           And they have all been like going through  
16 peer review also. Even it's not as rigorous as like  
17 National Academy of Science Review, at least we need  
18 to get our leadership division to approve. And then  
19 before that, we have to get a review, four to five  
20 internal reviewers to review them.

21           And then after I submitted them to  
22 Journal, the Journal also have reviewer they have

1 there, like three people and the editorial review  
2 board editor to review it.

3           So it's not like an eleven member panel,  
4 NIOSH panel, but at least it has been going through  
5 a long period of peer review.

6           So, again, like this is my own view, do  
7 not represent a NIOSH at this point. So whatever  
8 NIOSH decided to use, that would be NIOSH policy.

9           Thank you.

10          Any questions?

11          MR. HEINS: Bodo Heins from Draeger

12 Safety.

13           I cannot remember if I probably already  
14 gave you the suggestion. In the country where I  
15 live, in the north of Germany, in  
16 Schlesweig-Holstein, the capital city is Kiel.

17           And in Kiel, there is a university, and  
18 there is a professor who is working since several  
19 years on a survey for these dimensions.

20           Probably you should contact him because he  
21 is working a long time on it, and he has a lot of  
22 knowledge about that.

1 Thank you.

2 MR. ZHUANG: Good. I will get the  
3 information from you. Thanks.

4 MR. SPAMPINATO: Phil Spampinato from ILC  
5 Dover.

6 I couldn't tell from -- your presentation  
7 was very good, by the way, very comprehensive.

8 MR. ZHUANG: Thank you.

9 MR. SPAMPINATO: The any effect -- if any  
10 effect was there from deformities, for example, a  
11 broken nose, do you -- do you believe that the  
12 research and the data that you have would allow this  
13 95 percent successful fitting, even in the face of  
14 deformities?

15 In other words, were they part of your  
16 sample population and so on?

17 MR. ZHUANG: That need to be investigated.  
18 Right now, like, we just make sure that these the  
19 kind of boundary for the subject.

20 But, again, when you only sample 25, it  
21 could be in the middle. It could be on the edge.  
22 So whether, like once you select 25 and how good it

1 can fit the population, that need to be verified.

2 We cannot cram that.

3           But at least it cover the population,  
4 their facial characteristic, but how good -- and  
5 even by a certification test, you cannot be sure  
6 that it will fit everyone. No, that's not the case.

7           But then, like the panel, you can use it,  
8 so you can recruit subject. You can -- and do your  
9 own tests. But it will give you, yeah, good  
10 results, like from fitting characteristics  
11 standpoint.

12           MR. SPAMPINATO: Thank you.

13           MR. ZHUANG: Okay.

14           MS. DEMEDEIROS: Edna DeMedeiros, North  
15 Safety Products.

16           Ziqing, once it gets past the National  
17 Academies, because that's where it is now being  
18 reviewed, is NIOSH planning to adopt this and  
19 replace the Los Alamos panel for certification  
20 testing?

21           MR. ZHUANG: I guess that question can be  
22 answered later on. At this point, I am just working

1 on it. It will be up to policy branch.

2 I guess that Bill Newcomb is considering  
3 right now, and, yeah, Les also.

4 MR. BOORD: Yeah. I think in our  
5 presentations yesterday, we talked about our TIL  
6 program.

7 MS. DEMEDEIROS: Right.

8 MR. BOORD: And that would be the obvious  
9 place that we would -- that we have considered the  
10 panel, and we will continue to consider it.

11 So, yeah, I think eventually it will be --  
12 work its way into certification through our TIL  
13 program.

14 MS. DEMEDEIROS: Do you think it would  
15 also take over for the isoamyl acetate?

16 MR. BOORD: I think eventually, that's the  
17 vision.

18 MS. DEMEDEIROS: Okay. And it would be  
19 more -- go out like to a Leonard certification?

20 MR. BOORD: Yeah. Actually, the TIL  
21 program, the concept is that that will be addressed  
22 through rulemaking processes.

1 MS. DEMEDEIROS: Okay.

2 MR. BOORD: So I see these different  
3 research activities coming together in the TIL  
4 program going through rulemaking into our  
5 certification activities.

6 MS. DEMEDEIROS: Okay. All right. Thank  
7 you.

8 MR. PFRIEM: Dale Pfriem, ICS  
9 Laboratories.

10 For Les, first a plea, then a question.  
11 Please hurry up.

12 And then second, when you put this into  
13 the certification procedures, if you would consider  
14 both panel methodologies so that those of us who  
15 would choose the more complicated method and deal  
16 with that, but then not have to scour the cities,  
17 looking for a Size 2, for instance, you know, less  
18 work, if you could give us that option. And those  
19 who have 500 employees from which they can choose  
20 from test subjects, they can use the simplified  
21 method, if you know what I mean.

22 MR. BOORD: Yeah. I think it's a good

1 suggestion, and it certainly will be considered as  
2 we go forward.

3 MR. PFRIEM: Thanks.

4 MR. BOORD: Thank you.

5 NANOTECHNOLOGY AND PERSONAL PROTECTIVE EQUIPMENT

6 MR. SHAFFER: Let's thank Ziqing for his  
7 excellent presentation.

8 Obviously, I'm Ron Shaffer, and I'm going  
9 to be giving the presentation on nanotechnology. I  
10 want to start off by acknowledging my coauthors,  
11 Pengfei Gao in the front row here, and Sammy  
12 Rengasamy, who is in the second row there.

13 Pengfei has done all of the work that they  
14 will be talking about today related to protective  
15 clothing, and Sammy has led the contracts or  
16 conducted the studies involving respirators, so I  
17 wouldn't be up here talking if it wasn't for their  
18 efforts in getting this presentation together.

19 This is the overview of the talk today.  
20 To start off, I will just tell you a little bit  
21 about nanotechnology and why there is some interest  
22 in it.

1 I'm going to spend a lot of time talking  
2 about the NIOSH document that's out on the web now.  
3 It's called our, Approaches to Safe Nanotechnology  
4 document. And because all of the findings and  
5 pieces of information are taken right out of that  
6 document today.

7 And then I will talk about what efforts we  
8 have done, literature studies and measurements on  
9 respirators, respirator filter media, and then  
10 protective clothing.

11 So what are nanoparticles? The definition  
12 is listed here. It is particles having a diameter  
13 between one and a hundred nanometers. So that's,  
14 you know, less than .1 micron sized particles, so  
15 they are -- let me see if I can -- so you are  
16 looking at basically right in this range and on  
17 down, so particles here and one smaller.

18 So those are the types of things that  
19 would be the smogs, fumes, tobacco smoke, viruses  
20 are particles in that size range.

21 Those are all naturally occurring or  
22 incident particles. What most people are concerned



1 about now are what is sometimes called engineered  
2 nanoparticles. So those would be things like carbon  
3 nanotubes, quantum dots, and things like that,  
4 things that are grinded -- not grinded, but grinded  
5 or milled during manufacturing that produce very,  
6 very small particles.

7           In fact, you know, that is becoming more  
8 common today. I mean, now you have got -- you  
9 certainly can buy pants from Dockers that have a  
10 nanocoating on them, your nanopants.

11           Nanoparticles are used in coatings in  
12 tennis balls. They are putting carbon nanotubes in  
13 the panels for car parts, for the autobody parts for  
14 a car.

15           So nanotechnology is expanding in its  
16 growth, and there has certainly been a lot of  
17 concerns that have raised recently about the health  
18 concerns of worker exposure to nanoparticles.

19           And this really isn't coming from NIOSH.  
20 This is coming from the manufacturers, the people  
21 that actually make those types of the products are  
22 coming to NIOSH and saying, How should I outfit my

1 employees? What type of respirators should they be  
2 wearing? What type of clothing should they be  
3 wearing?

4           And so we are being almost dragged into  
5 this by the large number of responses we are getting  
6 for questions.

7           So this is a slide that just outlines some  
8 of those health concerns. Make it very clear, I'm  
9 not a toxicologist, and everything that is listed on  
10 this slide is taken from the document that is shown  
11 on the slide here.

12           This is the -- NIOSH's Approaches to Safe  
13 Nanotechnology document. It's available on the  
14 website. I have got the link there. Certainly with  
15 that, you can contact me. I'll be happy to send you  
16 a PDF copy of this report.

17           Basically it summarizes everything that  
18 NIOSH knows about nanoparticles and nanotechnology  
19 and the Occupational Safety and Health concerns.

20           This document was generated by our -- we  
21 have a NIOSH steering committee I will talk about on  
22 the next slide that has generated this document.

1           If you go to that website and you look at  
2 the -- and you download the document, there is  
3 actually links on there where you can provide  
4 comments. There is a Federal Registry notice that  
5 has been set up to provide comments on our approach.

6           So if you think that we have missed some  
7 key literature references or we are understating or  
8 overstating the problem, please feel free to put  
9 comments into that docket, which you can get to  
10 through the website.

11           So I'm not going to read the words on  
12 here. I specifically just want to point out the  
13 third bullet, because the key point there is that  
14 the nanoparticles, generally speaking, have a larger  
15 surface area than the larger particles. That  
16 surface area is what gives them their great  
17 properties and why they are being introduced into so  
18 many products today. But it is also the reason why  
19 there is some additional health concerns.

20           So in the NIOSH Nanotechnology Research  
21 Steering Committee, the NTRC, it's a  
22 cross-divisional group. NPPTL has four

1 representatives, myself, Pengfei, Sammy, as well as  
2 George Bokosh (phonetic) who leads in the  
3 application side, we are looking at all aspects of  
4 the problem.

5           So we have got research projects in  
6 toxicology, risk assessment, measurements. There is  
7 even some interest now in looking at, you know,  
8 explosions and things like that. So it's a broad  
9 based program.

10           Obviously at NPPTL, our focus is in the  
11 controls area, in particular, PPE.

12           So, you know, why are people interested in  
13 this? Well, it has been brought to our attention  
14 that there is some concerns out there that  
15 nanoparticles could penetrate through PPE at higher  
16 rates than larger particles.

17           And it's not just, you know, my opinion on  
18 that. That has actually been documented in probably  
19 20 or more research gap reports that have been  
20 written by a number of government agencies.

21           EPA, UK's Health and Safety Executive, all  
22 have indicated that PPE studies should be high

1 priority to make sure that the smaller particles  
2 don't penetrate at a larger rate than the larger  
3 particles.

4           In fact, there even was a recent hearing  
5 in Congress on this issue where they emphasized that  
6 more research really needs to be done on the  
7 occupational safety and health aspects of  
8 nanotechnology.

9           So we initiated two research projects, one  
10 looking at air purifying respirators and one looking  
11 at protective clothing.

12           We recognize that we can't do this alone,  
13 and we have established a number of partnerships.  
14 The big one that we established this summer was a  
15 memorandum of understanding with Dupont.

16           The Dupont company leads a consortium of  
17 about 15 to 18 large companies, the Intels, Proctor  
18 & Gambles of the world, that have a complementary  
19 research program to also look at a lot of the same  
20 issues.

21           So the memorandum of understanding spells  
22 out how we are going to collaborate with them to

1 share data, make sure that we are using common test  
2 platforms so that we can mutually get the best kind  
3 of data published in the review editor.

4           Also ASTM and ISO have been using some of  
5 the NIOSH reports in developing new standards.

6 There is an E56 committee at ASTM that looks at  
7 nanotechnology, and they have a subgroup that looks  
8 at occupational safety and health.

9           And ISO also has a committee that is  
10 looking at this.

11           In addition, we have formed some  
12 partnerships with universities, and I will talk a  
13 little bit later about the work we have done with  
14 the University of Minnesota Center for Filtration  
15 Research.

16           So I will start off, I'll talk about  
17 what's in the safe working practices document from a  
18 respiratory protection aspect.

19           This slide just shows, it's the standard  
20 model describing single-fiber filtration theory,  
21 showing the basically the four mechanisms that  
22 particles get captured.

1           So on the X-axis is particle diameter, and  
2 on the Y-axis is filter efficiency.

3           I will interchangeably use penetration,  
4 which is just one minus -- penetration is basically  
5 the inverse of the efficiency. So if something is a  
6 hundred percent efficient, that means there was zero  
7 percent penetration. So I use those  
8 interchangeably.

9           So in this case, a higher number is good.

10          So filtration theory is and has been  
11 experimentally confirmed very well down to, say,  
12 about 20 nanometers, 20 nanometer particles, which  
13 is about the same size limit that the -- on some of  
14 the TSI commercial filtration systems cut off at.

15          So there is very good data down to there.

16          What's less, at least well experimentally  
17 verified is what happens to the smaller particles.  
18 In fact, there was one paper that was published as  
19 an abstract at a filtration conference that  
20 suggested that there was some -- an effect called  
21 the thermal rebound effect, that the particles  
22 literally bounced through the filter, particles less

1 than 20 nanometers.

2           And so what we decided to do was to  
3 collect some experimental data to verify that the  
4 filtration theory, single-fiber theory, is indeed  
5 intact for those smaller particles and valid.

6           So we -- at this time, we didn't have our  
7 research aerosol lab set up, so we got a contract  
8 awarded to University of Minnesota Center for  
9 Filtration Research, had them construct a  
10 nanoparticle test system, measured particles smaller  
11 than 300 nanometers through various types of filter  
12 media.

13           So these were not actual respirators, but  
14 they were the filter media. And just to verify that  
15 filtration theory holds for the smaller particles.

16           That report was -- that work was  
17 completed, and a final report was given to us in  
18 April. I'm pleased to say that that's actually  
19 available now on the NPPTL website. If you go there  
20 and look under research programs, you will find a  
21 link to the Minnesota report.

22           We are trying to get that cross-posted on



1 the NIOSH nanotech website so that you can get it  
2 from a number of different places if you want to  
3 take a look at.

4           But the Minnesota group is in the process  
5 of getting this published in a peer review journal  
6 as well. So the data will be available a number of  
7 different ways..

8           I will talk in the next few slides about  
9 the conclusions and some the data for the Minnesota,  
10 but I just wanted to mention that we have continued  
11 along with this project. And Sammy Rengasamy has  
12 developed a proposal that is currently in internal  
13 peer review right now that would extend the studies  
14 where we can basically are building a test system at  
15 NPPTL.

16           We are going to validate the previous work  
17 with NIOSH-approved respirators and also going to  
18 look at the effect of particle size on the face seal  
19 leakage.

20           So this is the test system that Minnesota  
21 developed. And I'm not going to go through all of  
22 the details here, but just wanted to point out that

1 they used silver nanoparticles in the size range of  
2 about three to 20 -- three nanometers up to about 20  
3 nanometers size is the particles that you can  
4 generate with this furnace based system.

5           And this is some data from Hollingsworth  
6 (phonetic) and Vo's fiberglass filter media. So,  
7 again -- let's see if I can do this -- so, again, we  
8 are looking at penetration as a function of particle  
9 size for four different filter media.

10           And this data suggests that the smaller  
11 particles get captured very well by the filter  
12 media. In fact, for some of the particle sizes,  
13 they basically were not able to get any of the  
14 particles through the filter media.

15           They also looked at electret filter media.  
16 And again, you see a similar effect, that the  
17 penetrations are very small for the very small  
18 particle sizes. And this is through five different  
19 types of filter media.

20           Through the Center for Filtration  
21 Research, 3M is a member of that. And they  
22 collaborated with us, and Minnesota contributed some

1 data, where they tested the same types of filter  
2 media, but tested them at a setup in their  
3 laboratory.

4           So what you see here is combined, the data  
5 from the previous slide with some of the 3M data, so  
6 you can see the distribution from, say, three  
7 nanometers up to 300 nanometers or so.

8           So you see a very good connection between  
9 the two lines and, again, confirming that the  
10 smaller particles do get captured very well by the  
11 electret filter media. And that you see a less  
12 penetrating particle size in the range of 50  
13 nanometers or so for those types of filter media.

14           So the summary from the Minnesota contract  
15 was that penetration decreased with decrease in  
16 particle size less than 20 nanometers.

17           The filtration theory or the filtration  
18 data supported the single-fiber filtration theory  
19 down to three nanometer in size. And we saw no  
20 evidence for thermal rebound.

21           Since the Minnesota work has been done, a  
22 group in Germany has also done similar experiments

1 and found similar findings. And I think there are  
2 other couple of research groups across the country,  
3 the Dupont folks as well, that are also in the  
4 process of -- with different particles generation  
5 system, are finding similar results.

6           So this is the interim recommendations  
7 that are in the Approaches to Safe Nanotechnology  
8 document.

9           Obviously our advice is still that  
10 respirators may be necessary when other control  
11 methods are not adequate.

12           There are no exposure limits for  
13 engineered nanoparticles, and the decision is still  
14 based on professional judgment. But what we can say  
15 about the respirators is that there certainly has  
16 been no deviation from single-fiber theory for the  
17 particle sizes that we have tested and Minnesota has  
18 tested.

19           And that you get -- when used within the  
20 context of an OSHA respiratory protection program,  
21 it is likely that the respirators will be useful for  
22 protecting workers.

1            Now I'm going to switch gears and talk  
2 about protective clothing.

3            Whereas we had a lot more data on the  
4 respirator side, we found a lot less information in  
5 the protective clothing. And, in fact, we found  
6 that there were no guidelines currently available to  
7 guide end users to select clothing or gloves for  
8 prevention of dermal exposure to nanomaterials.

9            There has been little data published on  
10 penetration. There is an ASTM standard that uses a  
11 27 nanometer bacteriophage, and there is at least  
12 some data out there on larger particles.

13           We initiated a research study that  
14 actually looked at a broader set of issues on  
15 basically systems level aerosol testing for  
16 protective ensembles.

17           To that study, we have added some  
18 nanoparticle work. And Pengfei is the project  
19 officer for that.

20           I was at a recent conference just a couple  
21 of weeks ago, an elevated wind studies conference in  
22 September. I came across a number of military

1 reports that actually have studied particle  
2 penetration through clothing, which was something  
3 that we hadn't come across in our literature search.

4           The military studies are often buried in a  
5 government report that's very hard to find or in an  
6 obscure test method. But at the meeting, I did get  
7 some contacts, so we are in the process of gathering  
8 this new information.

9           But this slide just summarizes essentially  
10 some of the presentations that were at that  
11 conference, basically that aerosol penetration of  
12 permeable fabrics is also particle size dependent.

13           And the Battelle work in particular found  
14 that penetration was consistent with respirator  
15 filtration theory, although the penetration values  
16 were much larger because they are not designed to be  
17 respirator filter media, they find the most  
18 penetrating particle size and the very smallest  
19 particles, the nanoparticles, were captured much  
20 better than the larger particles.

21           What we have been focusing on at NPPTL is  
22 developing a passive aerosol sampler that would be

1 able to be placed on a person in a systems level  
2 test to measure particle penetration, something that  
3 would use minimal flow.

4           The feeling is that active sampling  
5 methods may overestimate particle penetration  
6 because you are adding an additional driving force.  
7 And our belief is that samplers should not disturb  
8 the PPE wearer environment.

9           So the concept that Pengfei and his team  
10 have come up with is to use a magnetic sampler,  
11 basically to use a very small magnet. And then use  
12 a challenge particle which has magnetic  
13 susceptibility. So that when it comes in proximity  
14 to the magnet, basically it becomes attracted and  
15 gets trapped in there.

16           So the idea is you don't apply an external  
17 sampling force, just enough force to get the  
18 particle to stick to the magnet so that, during  
19 handling, it would stay there.

20           And, you know, there is a number of  
21 advantages to this type of method. You know,  
22 certainly it would be inexpensive, and also a wide

1 range of particle sizes would be available if we  
2 used some iron oxide particles.

3           The detection would be accomplished,  
4 basically, you would take the magnet sampler out,  
5 take it back to a lab, use either a Colorimetric  
6 method or some other more sophisticated methods,  
7 SEMs or TEMs, or you can use some magnetic  
8 susceptibility.

9           I should say that this project was part of  
10 the project that went out for external peer review,  
11 and we are still responding to the some of the  
12 comments that -- that some of them did raise on some  
13 of the issues of the detection methods, and we are  
14 revising the proposal based on that.

15           Some preliminary data -- and I should  
16 point out this was collected before our aerosol lab  
17 was developed, so Pengfei did his best with the  
18 facilities in our clothing research labs.

19           You will see sort of a homemade aerosol  
20 test system that we built, and of course it has  
21 updated in the last year.

22           So this was some data from last year,



1 actually. This just shows the characterization of  
2 the passive aerosol sampler response. Basically, we  
3 filled this bag with an aerosol concentration just  
4 to see if the response of the sampler was  
5 proportional to concentration in the chamber.

6           We looked at two prototypes, and this is  
7 of the data that we got. You see that, yes, you do  
8 get a proportional response so that the more -- or  
9 the higher level of concentration of particles in  
10 that chamber, the more material is collected on the  
11 sampler.

12           It's not a -- the variation is more than  
13 what we would like to see, but we were happy to see  
14 that there was a proportional response. Certainly  
15 additional work is being done to validate this and  
16 to improve the method.

17           We also did an experiment that we actually  
18 tested the penetration through a swatch of fabric,  
19 in this case, a Nomex fabric. So we basically used  
20 an ASTM F-739. It's a vapor penetration cell. Put  
21 particles in the top half, put the fabric in the  
22 middle, and put the magnetic sampler at the bottom.

1           So there was an ambient condition, so we  
2 were not drawing the particles through the fabric  
3 sample. We used a prototype one for these  
4 measurements.

5           This is some the data that we got. This  
6 just shows the column on the -- the first column  
7 under the cell just shows type of fabric that was in  
8 the cell at that time. Nomex parafilm, which  
9 basically would be a blank. It would be nothing --  
10 well, nothing would get through an opening, which  
11 would be everything should get through.

12           And so this is just some of the average  
13 numbers collected and the standard deviation and the  
14 number of experiments done.

15           We do agree that the variation is a little  
16 higher than what we would like to see. But as a  
17 proof of concept, we were encouraged that you could  
18 get a protection factor from a system, a crude setup  
19 like this. And it -- for a Nomex fabric such as  
20 this, we got a protection factor of six.

21           This is data that is a little more current  
22 from the aerosol research lab. Pengfei has built a

1 system this summer that generates a monodisperse  
2 nanoaerosol stream. This just shows a photograph of  
3 that setup. The data in the lower half here is  
4 basically the particle size distribution from three  
5 different experiments.

6           And then this just shows the long-term  
7 stability of that aerosol stream. So the next set  
8 of experiments would be to take this aerosol stream  
9 and basically put fabric samples in sort of a wind  
10 tunnel type configuration, a miniature one, and then  
11 subject that particle stream to the fabrics and then  
12 detect what comes out on the other side.

13           So this is just some preliminary data that  
14 we have been collecting.

15           So I want to summarize the clothing  
16 results.

17           The prototype, based on magnetic sampling,  
18 does allow a minimal or sometimes we call it a zero  
19 flow collection of the iron oxide aerosols. We do  
20 get a proportional response, but we feel that  
21 additional characterization is necessary.

22           We think that it will be applicable for

1 bench scale fabric penetration. Its applicability  
2 has already been shown, but further development is  
3 underway.

4           And finally, we do need to incorporate and  
5 analyze the results from some of these military  
6 studies to update the NIOSH recommendations so that  
7 that additional information is available to a  
8 broader audience.

9           And with that, I will be happy to take any  
10 questions.

11           At this point, we will -- some extra  
12 slides. We turn it over to Jon Szalajda, who is  
13 going to talk about reusability of filtering  
14 facepiece respirators.

15       REUSABILITY OF FILTERING FACEPIECE RESPIRATORS

16           MR. SZALAJDA: At this point, you know,  
17 with everyone having the PowerPoints there, I wish  
18 there was some sort of reward I could give you all  
19 for hanging in there until the end. But  
20 unfortunately, I think the only reward I can give  
21 you is keeping my comments brief.

22           With that, we will move into the

1 presentation.

2 I think at least a little bit of  
3 information to keep in mind is that the planning  
4 efforts for our research program and the reusability  
5 and handling of filtering facepiece respirators  
6 started some time ago. And it has been a very, very  
7 dynamic type of road that we have been on.

8 I think a couple of things of note above  
9 and beyond what I had mentioned yesterday was the  
10 ILM report that the Department of Health and Human  
11 Services requested, you know, in trying to identify  
12 issues associated with the reuse of medical masks  
13 and N95 filtering facepiece respirators.

14 And this topic has also, believe it or  
15 not, gotten the interest of Congress. And if you go  
16 through the current appropriations language, you  
17 would see that the Senate is recommending that we do  
18 an evaluation of respirators for effectiveness  
19 against transmission of influenza and other  
20 pathogens.

21 So what really precipitated that ILM  
22 study, DHHS's request to the National Academies to

1 have the Institute of Medicine conduct this type of  
2 evaluation.

3           I think when you look at healthcare  
4 recommendations for respiratory protection, CDC  
5 recommends the use of NIOSH certified N95 filtering  
6 facepiece respirators or higher for dealing, at  
7 least as far as providing the minimum level of  
8 respiratory protection for healthcare workers  
9 dealing with the influenza viruses or other  
10 infectious aerosols.

11           And it's apparent that, you know, in the  
12 event of a pandemic, looking historically at other  
13 pandemics that have occurred in the past century,  
14 that healthcare workers and the general public will  
15 potentially have an increased reliance on these  
16 types of respirators for infection control.

17           What did the IOM tell us? Well, I think  
18 the one recommendation that a lot of people latched  
19 onto is there is no recommendation for  
20 decontamination. But, however, if you go through  
21 and you specifically look at the specific  
22 recommendations that the IOM put forward, they had

1 recommended a couple of things.

2           And few of the things we are addressing in  
3 this research program deal with the efficacy of  
4 decon methods that a hospital setting could use on  
5 respirators to decontaminate the filtering  
6 facepieces without causing a negative impact on the  
7 respirator integrity.

8           The other aspect of that is the handling  
9 aspect, and I think Ron had mentioned earlier today  
10 this is probably the last time that you will see the  
11 title of this project the way it is.

12           We will probably modify the title to  
13 reflect the handling aspect of the system as well  
14 because, you know, part of the issue is if you do  
15 have a filtering facepiece respirator that has been  
16 contaminated with a viral agent, you know, what  
17 happens with regard to the handling of that  
18 respirator, what types of controls need to be in  
19 place to avoid an individual from contacting the  
20 respirator and becoming contaminated that way.

21           Another aspect of that also is looking at  
22 the re-aerosolization of the viruses off of the

1 respirator itself.

2           And I think one of the things that's going  
3 to be important, an important product out of this  
4 research is that when you think of in general that  
5 hospitals tend to have lower concentration of  
6 particulates in their settings, and the reuse may be  
7 more dependent on the infection control procedures  
8 that we evaluate in this process than the actual  
9 decontamination proceedings themselves.

10           This is the fun part of the presentation,  
11 at least as far as how we are going to do the work.

12 And I want to at least identify a couple of the key  
13 players that are going to be doing some of the  
14 initial tasks.

15           Dennis Viscusi is sitting up here in the  
16 front in the yellow shirt. He is going to be our  
17 task leader for task one, which is going to look at  
18 the effect of decon on filtering facepiece  
19 respirators' performance.

20           And as part of that task, we are going to  
21 be looking at things, doing things, the base types  
22 of research activities that you would expect in any



1 type of study. You know, we are going to do a  
2 literature survey looking at trying to identify  
3 decontamination methods that could potentially be  
4 used against filtering facepiece respirators.

5           And in particular, I then think when you  
6 think about the materials of construction that roll  
7 into the fabrication of these types of systems, we  
8 are going to try to focus our literature survey to  
9 look at decon methods that may have been developed  
10 that specifically look at those materials.

11           We are also going to do some screening  
12 studies as part of this evaluation. Initially we  
13 are going to try to identify potentially up to 10  
14 different types of decontamination methods for  
15 consideration and look at doing some initial  
16 screenings with N95 respirators and P100 respirators  
17 under two different conditions, either, you know,  
18 maybe depending on the type of decontamination, but  
19 maybe things along the lines of sprays or soaking  
20 the respirator in the solution and then determining  
21 any degradation in the filtration performance of the  
22 respirator.

1           Once we go through that initial screening,  
2 then we are going to go and expand and do some  
3 additional studies looking at a broader population  
4 of filtering facepiece respirators.

5           We are going to add surgical masks/N95  
6 type systems. And we are also going to look at  
7 filtering facepiece respirators that possess some  
8 type of antiviral sterilization types of  
9 capabilities that are integrated into the respirator  
10 itself.

11           When you look at task two, the intent is  
12 to develop a standard test procedure, a reproducible  
13 test procedure that can quantify decontamination.  
14 effectiveness. That effort is going to be led by  
15 Evanly Vo, who is sitting in the back of the room.

16           And the intent here is to look at  
17 developing a generic methodology that could be  
18 applied to any type of decontamination agent that  
19 could be used in the decontamination of a filtering  
20 facepiece respirator.

21           We are intending with this effort to  
22 collaborate with the ASTM F-23 committee to help us

1 with the development of that methodology.

2           Task three is going to address the  
3 concerns, the infection control procedure concerns  
4 about the survivability of a virus on the -- virus  
5 simulant on the filtering facepiece respirator where  
6 we are going to contaminate filtering facepiece  
7 respirators under controlled conditions and see what  
8 happens.

9           You know, it might be the case that in a  
10 contaminated respirator, if it's left alone for a  
11 day or two days, that may be enough to allow the  
12 reuse of that type of system.

13           Task four, the re-aerosolization, is going  
14 to be conducted on a contract that we have with the  
15 Battelle Columbus Laboratories, and this is -- we  
16 selected Battelle to do this work.

17           They had done initial studies for us  
18 using -- on re-aerosolization of virus particles,  
19 and we felt that the contract with Battelle was a  
20 good fit to conduct this effort for us.

21           When you look at the task and our  
22 relationships, the task five and six are really

1 dependent on the outcomes of one and two.

2           And one of the things that I think it's  
3 important to note when you are looking at the  
4 potential of developing a method, I mean, from our  
5 perspective, this project will still be a success  
6 even if the end result is there is no decon method  
7 that can be used to decontaminate, effectively  
8 decontaminate a filtering facepiece respirator.

9           You know, the one thing that we have noted  
10 and the IOM noted as part of the research was there  
11 really is a lack of research in this area.

12           And we are hopeful that by going through,  
13 you know, the comprehensive screening effort that we  
14 will be able to make a determination whether or not  
15 there are methods that could be used and then take  
16 them to fruition.

17           If not, then that's good information to  
18 have that can be relayed to the stakeholder  
19 community as a whole.

20           The other aspect to keep in mind, too,  
21 with this process is, this is really a respirator  
22 shortage emergency type of situation.

1           We don't anticipate, you know, any  
2 guidelines, at least as far as the methods are  
3 concerned, being implemented and put into practice  
4 unless there is an actual pandemic where there are  
5 respirator shortages in place. You know, this is  
6 not something to, you know, circumvent existing  
7 recommendations for disposal of contaminated  
8 respirators.

9           Again, it is addressing an emergency, you  
10 know, type of situation where there could be a  
11 respirator shortage.

12           But just to kind of finish the effort with  
13 the slides, in task five, we are going to take the  
14 results of task one and task two and take the method  
15 that was developed in task two, look at the  
16 promising characteristics identified -- or promising  
17 decontamination methods that were identified in task  
18 one, marry those two things together and see what  
19 happens.

20           Another product of task five is going to  
21 be when you look at the types of systems that have  
22 the antiviral capabilities, we are going to evaluate

1 in task five what the reactive by-products are of  
2 those types of systems, whether or not when you --  
3 excuse me -- whether or not there are any  
4 by-products that we should be concerned about coming  
5 through the respirator into the breathing zone for  
6 people that are wearing those types of systems.

7           Task six ties things together. Once you  
8 have a decontaminated respirator, how does that  
9 affect -- how does any changes in the integrity  
10 affect the fit of the respirator to the individual.  
11 And this will all be tied up at some point in a nice  
12 final report which could be used to generate  
13 guidance documents for the stakeholder community.

14           One thing that some of you I know have  
15 noted that's in -- been recently published in the  
16 Federal Register notice is an announcement where we  
17 are looking to try to identify some of these  
18 antiviral technologies to consider as part of the  
19 candidate respirators that we are going to evaluate  
20 in the various tasks.

21           And this is a hierarchy of how we are  
22 going to make a selection on the types of

1 respirators that are going to be used in the system.

2           The first emphasis is going to be looking  
3 at existing products that are currently in the work  
4 force that meet and conform to NIOSH part 84  
5 requirements.

6           Then we will go from there, looking at  
7 products that may be in the loop to be certified or  
8 products that come from manufacturers that have  
9 existing NIOSH certifications for other types of  
10 respirators.

11           But we also wanted to leave the  
12 announcement open enough that, if there was a novel  
13 technology that's currently being explored in the  
14 industry that could have a widespread application,  
15 we wanted to be able to address that as part of the  
16 study.

17           At this point, if you are interested in  
18 participating, all you need to do -- I'm the contact  
19 point in the Federal Register. All you need to do  
20 is send me an email or a letter just identifying  
21 your interest in participating or having your  
22 products being considered as part of the process.

1           We are not looking for hardware or  
2 anything else at this time. We are just looking to  
3 identify interest in the project. And then we will  
4 go through this hierarchy of consideration that was  
5 in the Federal Register notice, at least as far as  
6 to select potential candidates for inclusion in the  
7 project.

8           One thing I did forget to mention, I was  
9 talking about the research, the research itself.

10           We are in the process of developing a  
11 proposal. We have developed a proposal that we are  
12 going to use to execute the various tasks in the  
13 study.

14           Right now, we have gone through an  
15 internal review of the proposal within NPPTL.  
16 Dr. D'Alessandro has gone out looking for external  
17 peer reviewers looking for a combination of  
18 manufacturer industry representatives, academia, and  
19 stakeholders to review the proposal and give us  
20 suggestions and critique the work that we wanted to  
21 execute.

22           What I would suggest was, depending on



1 where you are in those different categories, ISEA  
2 and IAHA, the Industrial Hygiene Association, have  
3 the lead, at least in terms of identifying potential  
4 proposal evaluators.

5           So if you are interested in being part of  
6 the evaluation process, I would suggest you could  
7 talk to Dr. D'Alessandro or talk to your contacts at  
8 those organizations to indicate your interest in  
9 being involved.

10           The schedule, at least as far as how it is  
11 currently laid out, is resource driven. I mean  
12 based on the existing workloads within the branch  
13 and the other activities going on and the amount of  
14 resources that were identified by CDC to conduct the  
15 program, we have laid out a schedule to bring the  
16 project to fruition.

17           Where do we expect to end up with outcomes  
18 for this project? I think there's three  
19 different -- there is three specific areas where I  
20 think we are going to expand the knowledge base in  
21 these areas.

22           One is the performance data on the

1 filtering facepiece respirators that incorporate  
2 decontamination capabilities. Now, these are  
3 relatively new products to the market.

4           We would like to expand our knowledge base  
5 on them as far as their effectiveness and as far as  
6 any issues that may be associated with the use of  
7 those types of respirators.

8           Also, depending on how the project goes,  
9 there is a consideration for making modifications to  
10 what CDC currently recommends for reusability of  
11 filtering facepiece respirators.

12           And ultimately the product will come up  
13 with an output that can be used or can be  
14 established and documented in an ASTM procedure  
15 where others in industry or academia can go out and  
16 do their own studies to look at decontamination  
17 effectiveness on filtering facepieces with other  
18 agents.

19           Now, when you look at how we are  
20 conducting the program, we are going to be using a  
21 viral simulant which will hopefully replicate or  
22 represent, you know, animal viruses and is based on

1 existing research that's been done.

2           But that's not to say that there isn't an  
3 opportunity for work in other laboratories to look  
4 at other types of viruses and other types of  
5 settings to implement this procedure to develop  
6 knowledge and use that knowledge to protect workers.

7           So with that, I would be happy to take any  
8 questions.

9           MR. BERGMAN: Excuse me. Mike Bergman,  
10 the SEA Group.

11           Jon, thank you very much for your  
12 presentation, and it is a very important study that  
13 you are undertaking.

14           I would like to ask that you also consider  
15 looking at elastomeric half-masks with mechanical  
16 P100 filters as a complement to your study in that  
17 that type of system will also be a protective  
18 measure in the event of a pandemic influenza.

19           Thank you.

20           MR. SZALAJDA: Thank you, Mike.

21           I think that's a good consideration. You  
22 know, when you look at the CDC recommendations of

1 using an N-95 or higher, you know, half-mask  
2 respirators are used within the various settings,  
3 and that could be a good consideration for us to  
4 consider.

5 MR. GREEN: Larry Green, Syntech  
6 International.

7 And I was wondering about the studies  
8 regarding PAPRs for that. We have a lot of  
9 customers that -- in the health care that want to go  
10 to the even higher levels of protection and use  
11 PAPRs to get the reduced CO2 loadings for those  
12 critical personnels.

13 And I'm sure they would like to -- this --  
14 all of this study is very closely related to what  
15 our customers are telling us that they want to see.

16 MR. SZALAJDA: Okay. That's a good  
17 comment as well. Thank you.

18 I guess, again, when you look at the  
19 initial approach to the project, we are closely  
20 following the recommendations from the IOM looking  
21 at the filtering facepiece respirators, but that's  
22 not say that eventually a project could evolve to

1 look at other categories.

2 MR. SELL: Bob Sell, Draeger Safety.

3 This is a kind of a two-person question by  
4 another member of the audience, but will you  
5 evaluate the effect on the electrostatic charge on  
6 some of these filtering facepieces after the  
7 decontamination?

8 MR. SZALAJDA: Well, the approach that we  
9 currently have defined is to look at doing the  
10 particulate challenges using sodium chloride that is  
11 currently done, you know, for the certification of  
12 filtering facepiece respirators.

13 So we will look at the contamination --  
14 we'll do the contamination/decontamination, and then  
15 measure the filtration efficiency following that,  
16 and then make a determination of the delta between  
17 the untested -- or the unchallenged filtering  
18 facepiece and then the challenged.

19 Great. Well, thank you very much.

20 I guess what I would like to do before --  
21 while Les is in the process of coming up, somewhere  
22 in your pamphlet, there is another survey to be

1 filled out.

2           And if you can take 30 seconds and fill  
3 that out and start filling that out while Les is  
4 doing his concluding remarks, I don't think he will  
5 mind.

6           Thank you very much.

7           MR. SHAFFER: Let's thank Jon for his  
8 talk.

9                           CLOSING REMARKS

10           MR. BOORD: Jon, thanks for that last  
11 comment. That was the first thing on my list.

12           So, yes, if you could fill out the  
13 customer satisfaction surveys, we would greatly  
14 appreciate that.

15           And, again, remember that the lower  
16 left-hand corner has the date. There were two  
17 surveys; one for yesterday and one for today. So if  
18 you do that, we would greatly appreciate it.

19           And keeping true to schedule, we promised  
20 to conclude by 11:30, so after I take my one hour,  
21 we will be...

22           So I just have a few closing comments.

1           First of all, we certainly want to thank  
2 all of you for attending this meeting. We hope that  
3 the information that's been presented can be of some  
4 use to you, and we also hope that the result of the  
5 discussions and presentations have given you a  
6 greater awareness and understanding for, first of  
7 all, NIOSH, the institute, and some of the future  
8 directions and activities for the institute relative  
9 to the sector based program portfolio; the role that  
10 NPPTL has within the institute, and some of our  
11 programs and projects; and our operational  
12 strategies and focus for the laboratory.

13           And then, finally, the concepts and the  
14 ideas that we have and are building for the greater  
15 picture of the personal protective technology  
16 cross-sector for the institute.

17           The programs and the projects that we  
18 presented yesterday and today are a really good  
19 representation of the activities at the laboratory,  
20 but that's not everything.

21           There are projects and programs that have  
22 not been discussed during this meeting, but I think

1 they do give a very good cross-section of our  
2 activities.

3 I would encourage you to periodically  
4 visit our website for updates on various concept  
5 papers, concept -- standards development concept  
6 updates, and for other information relative to our  
7 research programs and ongoing activities.

8 You are certainly welcomed and encouraged  
9 to make contact with any of the researchers, program  
10 managers, or others from within the laboratory to  
11 share your ideas.

12 Yesterday, during the discussions, we  
13 mentioned the docket. And I think in your  
14 information package, you have the listing of all of  
15 the open dockets that we have for the laboratory.

16 And there will be additional docket  
17 numbers added for the PPT cross-sector and perhaps  
18 for some of our ongoing research activities.

19 So, again, I would encourage you to visit  
20 our website to stay familiar with our programs.

21 And, finally, I would just like to mention  
22 that, from our perspective, I think the meeting has



1 been very useful.

2           It is always good for us to -- you know,  
3 it is good to go through the motions to say you have  
4 outreach. It's good to get out there and try to do  
5 things.

6           But I think that for me, it has really  
7 been a very good experience to have the opportunity  
8 to share with you the things we are doing and to  
9 have the side bar conversations and discussions to  
10 further facilitate the information exchange.

11           I would look to trying to do a similar  
12 type meeting on an annual basis. I think, as I  
13 explained yesterday, our systematic way for  
14 strategically moving the organization forward is  
15 based on the federal fiscal year.

16           We go through our systematic strategic  
17 planning, and we kick off the year in the first of  
18 October. And if there changes made to our programs,  
19 new programs added, that's the time when it really  
20 takes effect.

21           So I think there would be benefit to  
22 having a similar meeting to this on an annual basis

1 to keep you informed of what we are doing, of our  
2 new programs, and our activities.

3           So your customer satisfaction surveys are  
4 very important to help us make that decision.

5           With that, I think we can adjourn this  
6 meeting. And, again, thank you for your time and  
7 your attention and your ideas.

8           Thank you.

9           (Whereupon, the proceedings in the  
10 above-captioned matter were concluded at 11:33 a.m.)

11

12

13

14

15

16

17

18

19

20

21

22

## 1 CERTIFICATE OF REPORTER

2 I, Joseph A. Inabnet, do hereby certify  
3 that the transcript of the foregoing proceedings was  
4 taken by me in Stenotype and thereafter reduced to  
5 typewriting under my supervision; that said  
6 transcript is a true record of the proceedings; that  
7 I am neither counsel for, related to, nor employed  
8 by any of the parties to the action in which these  
9 proceedings were taken; and further, that I am not a  
10 relative or employee of any attorney or counsel  
11 employed by the parties thereto, nor financially or  
12 otherwise interested in the outcome of the action.

13

14

15



---

Joseph A. Inabnet

Court Reporter

16

17

18

19

20

21

22